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The levonorgestrel intrauterine system, LNG-IUS 52 mg, is a highly effective and cost-
effective contraceptive, entailing minimal patient effort. Irregular bleeding patterns are 
common during the first months of use and constitutes one of the main reasons for 
discontinuation. Up to date, no standard treatment approach has been proven to resolve this 
problem. Mifepristone is a synthetic steroid hormone, acting mainly as an inhibitor of the 
progesterone receptor (PR) thereby preventing the effect of progesterone. Administration of 
mifepristone has been proven beneficial in numerous fields in reproductive medicine and 
exerts various effects depending on the dosage and stage of the menstrual cycle at treatment. 
Administration of low daily doses of mifepristone results in anovulation and endometrial 
suppression with subsequent amenorrhea. Continuous treatment with PRMs cause 
endometrial alterations previously thought to be similar to unopposed estrogen exposure, 
given the PR antagonistic effects of PRMs. These alterations are today recognized as 
progesterone receptor modulator associated changes (PAEC). They are considered to be 
benign and dissolves with the cessation of treatment. The molecular alterations resulting in 
their development are still unknown. The mechanism of action of steroidal hormones on 
breast tissue remains largely unidentified. Epidemiological studies show a positive correlation 
between number of menstrual cycle exposure and hormone therapy to the risk of breast 
cancer. While this increased risk has been believed to be mainly caused by estrogen, a 
growing body of literature suggest progesterone and progestins to play a central role. PRMs 
can be used as a tool to study the effects of progesterone and holds potential to prevent breast 
epithelial cell proliferation.  
Aim 
The overall aim of this thesis is to explore the effects of the PRM mifepristone on the 
endometrium and on human breast tissue in premenopausal women. The specific objectives 
were to assess whether inducing amenorrhea with mifepristone, prior to placement of the 
LNG-IUS, could reduce the bleeding irregularities during the first months of use. Another 
objective was to evaluate the endometrial morphology after continuous treatment with 
mifepristone following insertion of the LNG-IUS, without prior endometrial shedding. 
Furthermore, we sought to explore how mifepristone alters the transcriptomic landscape in 
human beast in vivo and the epigenetic alterations observed in the breast tissue following 
PRM treatment.  
Materials, methods and results 
Study I was a prospective, randomized, placebo controlled, double-blind trial including 
healthy women with regular menstrual cycles opting for the LNG-IUS 52 mg for 
contraceptive purposes. Fifty-eight women were randomized whereof 29 to the mifepristone 
and 29 to the comparator group. Study participants received mifepristone, 50 mg every other 
 
 
day or a comparator. The pretreatment period with mifepristone was 2 months, followed by 
the LNG-IUS insertion. Women kept bleeding diaries as per instruction for the pretreatment 
period and until 6 months after placement of the device. After removing drop outs and 
exclusions, 19 women in the mifepristone and 19 in the comparator arm contributed to the 
final analysis. Bleeding diary data were analyzed as rates of bleeding and spotting days 
(B/S%) per treatment cycle. The results showed a significant reduction of B/S% during the 
pretreatment period in the mifepristone arm compared to placebo. Following insertion of the 
device, no statistical difference could be seen between the two groups.   
Women in Study II originated from Study I. Endometrial biopsies were retrieved at baseline, 
prior to the pretreatment period with mifepristone or the comparator. A second biopsy was 
retrieved at 3 months following LNG-IUS placement, with the IUS in situ. Nine paired 
biopsies from the mifepristone and 8 from the comparator group, contributed to the final 
analysis. The specimens were analyzed by an expert pathologist who was blinded to the 
treatment. All baseline biopsies where benign. The second biopsies were all benign and 
showed, as expected, changes due to progestin effect on the endometrium. There was no 
presence of PAEC.  
Participants in Study III originated from Study I. Core needle breast biopsies were collected 
at baseline and after 2 months treatment with mifepristone or the comparator. Paired biopsies 
from 16 women in the mifepristone group contributed to the analysis. The changes on mRNA 
expression level at baseline compared to after mifepristone treatment were screened using 
RNA sequencing. Functional annotation and pathway enrichment analysis of the 
differentially expressed genes (DEGs) revealed genes mainly involved in extracellular matrix 
(ECM) remodeling.  
In Study IV, patient cohorts and databases were used to generate and validate a breast tissue 
specific epigenetic index. That index was subsequently used to assess breast tissue samples 
from three clinical trials, including Study I. Based on the results from this specific epigenetic 
index, PRM treatment could exhibit favorable results in the mammary gland from healthy 
women as well as women with increased risk for developing breast cancer.  
Conclusion 
The applied mifepristone treatment regimen could not demonstrate any significant 
improvement in bleeding disturbances following placement of the LNG-IUS compared to 
placebo. Continuous treatment with mifepristone and subsequent LNG-IUS insertion without 
prior endometrial shedding, could represent a safe alternative regarding PAEC endometrial 
safety. Transcriptomic alterations in the breast after treatment with mifepristone revealed 
pathways mainly involved in ECM remodeling. Furthermore, epigenetic and genetic 
alterations in the breast following PRM treatment seem promising and suggestive of further 
investigations regarding the potential beneficial effects of these compounds in the prevention 
of breast cancer.      
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1.1 PROGESTERONE AND PROGESTERONE RECEPTORS  
The progesterone receptor (PR) is a member of a class of proteins, the nuclear receptor 
superfamily of ligand-activated transcription factors, that regulates the expression of specific 
genes involved in female reproduction. There are two main forms of nuclear PR (PR-A and 
PR-B), arising from a single gene, exerting different biological effects in different tissue 
targets, also depending on their PR-A/PR-B ratio, the tissue content and on the hormonal 
status of the cell.  The two isoforms are structurally similar except that PR-B has 164 N-
terminal amino acids which PR-A lacks (1). The vast majority of our understanding regarding 
the role of the two isoforms derives from mice experiments although unbalanced expression 
ratio has been observed in endometrial and breast cancer in humans. In mice, PR-A seem 
mainly to control endometrial proliferation and PR-B breast epithelial proliferation and 
differentiation (1, 2).   
Some additional PR have been described, namely PR-C, -M, -S and -T, but their translation 
in vivo could not be supported (3). Moreover, a membrane-bound PR has been implicated in 
rapid non-genomic action of progesterone although its physiologic actions remain unclear; its 
binding capacity to progesterone seems low and in some experiments, there were no evidence 
of membrane-bound PR activation upon binding to progesterone (2, 4).  
The endogenous steroid hormone progesterone is the natural ligand of the PR and it is 
produced mainly in the ovary but also in the adrenal gland. Progesterone, derives from 
cholesterol, as the other steroid hormones, and it is a lipophilic molecule with a short half-life 
of only a few minutes. It is metabolized in the liver and its metabolites are excreted in the 
urine (5).   
Progesterone plays a pivotal role in the female reproduction exerting its action on the uterus, 
ovary, mammary gland and the hypothalamic-pituitary axis. The main effects of progesterone 
include control of ovulation facilitating the luteinizing hormone (LH) surge, GnRH pulsatility 
modulation, endometrial differentiation, control of endometrial receptivity and implantation, 
maintenance of pregnancy and inhibition of tubal and uterine contractility, prevention of 
cervical ripening, as well as differentiation of the mammary epithelium (6-8). In addition to 
its action in the reproductive system, P exerts biological effects in other organ systems, such 
















Figure 1. Upon ligand binding, the PR undergoes conformational changes and ultimately dimerization and DNA 
binding via specific progesterone response elements within target genes. Agonist-bound PR enhances 
transcriptional activation. Adapted from Chabbert-Buffet, Human Reproduction Update, 2005.                                                                                                                                      
Abbreviations: PR, progesterone receptor; PRE, progesterone receptor element; RNApol2, ribonucleic acid 
polymerase 2. 
Since progesterone is proven to be crucial for the normal function of the female reproductive 
system, it is of no surprise that aberrant progesterone responses are implicated in various 
benign reproductive disorders such as fibroids, endometriosis, adenomyosis, abnormal uterine 
bleeding and miscarriage, making the PR an important therapeutic target (2). Numerous PR 
ligands have been developed displaying a broad spectrum of action ranging from full agonists 
(progestins), used in oral contraceptives (OCs) and hormone (replacement) therapies, and 
ligands with mixed activities through to full antagonists later also known as PR modulators 
(PRMs) (7, 8). Due to the similarities of their steroidal backbone, various PR ligands have the 
ability to exert a variety of cross-reactivity properties with other steroid receptors, depending 










Figure 2. Chemical structures of progesterone (natural ligand of PR), levonorgestrel (progesterone receptor 
agonist – a progestin), mifepristone and ulipristal acetate (progesterone receptor modulators). 
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1.2 PROGESTERONE RECEPTOR MODULATORS 
Progesterone receptor modulators (PRMs) are synthetic ligands, mainly steroidal, which bind 
to PR isoforms and display antagonist or mixed agonist/antagonist effects in a tissue specific 
manner (8). Mifepristone was the first PRM developed, in 1980s. Since then, numerous other 
PRMs have been synthesized and investigated in trials, mainly in reproductive medicine but 
also in endocrinology, psychiatry and various types of cancer (1, 9). Up to date, there are two 
compounds licensed for clinical use in reproductive medicine. Mifepristone for termination of 
pregnancy and emergency contraception, and ulipristal acetate (UPA) for emergency 
contraception as well as treatment of uterine fibroids. In addition, mifepristone is licensed in 
the United States for patients with Cushing’s syndrome for control of hyperglycemia 
secondary to hypercortisolism (10). 
There is some inconsistency in the literature regarding the nomenclature of PR ligands that 
exhibit a variety spectrum of mixed activities. Some authors differentiate and categorize the 
compounds with profound agonistic properties as antagonists, while utilizing the term 
selective progesterone modulators (SPRM) for the compounds with more mixed properties; 
others include all these compounds in the SPRM family. In this thesis, the term PRM will be 
used and restricted to PR ligands exerting some degree of mixed agonist-antagonist activity to 
the PR receptor.  
Table 1. Clinical trials with PRMs in ClinicalTrials.gov. Trials with status completed, terminated or unknown 
are not included in this table. Search conducted on 18th of October 2020. 
PRM Name of trial  ClinicalTrials.gov  
Identifier 
Status 
Mifepristone BRCA1/2 and Effect of Mifepristone on the Breast NCT01898312 Recruiting 
 Study of Pembrolizumab and Mifepristone in Patients 
with Advanced HER2-negative Breast Cancer 
NCT03225547 Recruiting 
 Abraxane® With or Without Mifepristone for 
Advanced, Glucocorticoid Receptor-Positive, Triple-
Negative Breast Cancer 
NCT02788981 Recruiting 
 Study of Oral Mifepristone as Salvage Therapy in 
Patients with Advanced or Metastatic Non-Small Cell 
Lung Cancer 
NCT02642939 Recruiting 
 Enzalutamide and Mifepristone in Treating Patients 
with Metastatic Hormone Resistant Prostate Cancer 
NCT02012296 Recruiting 
 Efficacy of Mifepristone in Males with Type 2 
Diabetes Mellitus 
NCT03052400 Recruiting 





 Mifepristone for the Prevention of Relapses of 
Alcohol Drinking 
NCT02243709 Recruiting 
 Mifepristone and Misoprostol for 2nd Trimester 
Termination of Pregnancy in Burkina Faso 
NCT03269279 Recruiting 
 Mail Order Mifepristone Study NCT03913104 Recruiting 





 Telemedicine counselling for medical abortion NCT03461653 Recruiting 
 Mifepristone Induction for Fetal Demise (MIFD) NCT02620904 Active, not 
recruiting 





Mifepristone	 Evaluation of efficacy of two therapeutic strategies 




 Comparison of the Effectiveness of Treatment 
with Mifepristone and Misoprostol at the Same Time 
Compared to the Administration of Drugs at a 48-
hour Interval for Medical Abortion. 
NCT03440866 Active, not 
recruiting 
 Study of Clinic-based Versus Self-use of Medical 
Abortion Pills (MOC) 
NCT03727308 Recruiting 
 Clinical Evaluation of Cervical Ripening in the 
Outpatient Setting 
NCT04271722 Recruiting 
 Pilot Study of an Ambulatory Medical Abortion 
Service at 13-18 Weeks of Gestation in Colombia 
NCT04063904 Not yet  
recruiting 
 Second Trimester Medical Abortion (RAPM) NCT04160221 Recruiting 





Liver Safety Assessment During Ulipristal 
Acetate Treatment for Uterine Fibroids (LISA) 
NCT04004884 Recruiting 
 Observation of Long-term Effects on Endometrium 
and Uterine Fibroids in Women with Ulipristal 
Acetate Therapy 
NCT03972917 Recruiting 
 Non-interventional Study to Evaluate Long Term 
Safety, Prescription Management Patterns 
of Esmya in a Long-Term Setting (Premium) 
NCT02748460 Active, not 
recruiting 
 Breast Cancer – Anti-Progestin Prevention Study 1 
(BC-APPS1) 
NCT02408770 Active, not 
recruiting 
 Ovarian Function with ENG Implant and UPA Use NCT04291001 Not yet  
recruiting 
 Study Comparing Emergency Contraception 
Effectiveness in Women Who Weight ≥ 80 kg 
NCT03537768 Recruiting 
 Esmya Versus Surgery Before IVF/ICSI NCT04028986 Recruiting 
 Effectiveness of Orally Dosed Emergency 
Contraception in Obese Women – UPA (UPA-
Obesity) 
NCT02859337 Recruiting 
Onapristone A Study of Onapristone ER in Low Grade Serous 
Ovarian Cancer and Other Progesterone Receptor 
Positive Gynecologic Cancers 
NCT03909152 Recruiting 
 Onapristone as Preoperative Treatment for 
Postmenopausal Women with Hormone Receptor + 
and HER2- Breast Cancer (ONAWA) 




Transdermal or Oral Telapristone Acetate in Treating 
Patients Undergoing Mastectomy 
NCT02314156 Active, not 
recruiting 
 Oral CDB-4124 vs. Placebo in Stage I-II Primary 
Breast Cancer 
NCT01800422 Active, not 
recruiting 
Vilaprisan Assess Safety and Efficacy of Vilaprisan in Subjects 
with Uterine Fibroids (ASTEROID 5) 
NCT03240523 Active, not 
recruiting 
 Assess Safety and Efficacy of Vilaprisan in Subjects 
with Uterine Fibroids (ASTEROID 6) 
NCT03194646 Active, not 
recruiting 
 Assess Safety and Efficacy of Vilaprisan in Subjects 
with Endometriosis (VILLENDO) 
NCT03573336 Active, not 
recruiting 
 Assess Safety and Efficacy of Vilaprisan in Subjects 
with Uterine Fibroids (ASTEROID 4) 
NCT03400956 Active, not 
recruiting 
 Assess Safety and Efficacy of Vilaprisan in Subjects 
with Uterine Fibroids (ASTEROID 3) 
NCT03400943 Active, not 
recruiting 
 A Study to Assess the Safety and Efficacy 
of Vilaprisan in Japanese Subjects with Uterine 
Fibroids and Heavy Menstrual Bleeding (ASTEROID 
8) 
NCT03476928 Active, not 
recruiting 
Abbreviations: PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; ENG, etonogestrel; 
UPA, ulipristal acetate; IVF, in vitro fertilization; ICSI, intracytoplasmic sperm injection; ER, extended release; 




Mifepristone (RU 486) is the most studied PRM acting mainly as a PR antagonist (8). Its 
effect, as for other PRMs, is well known to be dependent on the dose and dosage given, the 
stage of the menstrual cycle and PR expression in the target tissue at time of administration 
(8, 11). Mifepristone in a single dose, administered immediately after ovulation have been 
shown to inhibit endometrial development and receptivity. When given in the mid luteal 
phase of the menstrual cycle it induces uterine bleeding in a dose-dependent manner (12). 
Low continuous doses cause anovulation and a high fraction of amenorrhea with decreased 
endometrial proliferation, also in a dose dependent manner (13, 14). 
The binding affinity of mifepristone for the PR is about 2.5-5 times higher than that of the 
natural ligand progesterone (15).  Given this ability and its antagonistic properties, it is of no 
surprise that mifepristone, as well as other PRMs, have been studied for numerous 
gynecologic indications. Mifepristone is currently approved as a single dose treatment for 
clinical use in abortion care in combination with a prostaglandin analogue, for cervical 
ripening prior to surgical abortion (16), induction of intrauterine fetal death (17) and 
emergency contraception (18). Long-term administration of mifepristone is not approved but 
nevertheless comprehensively studied in various clinical trials demonstrating its potential use 
for contraception (19), medical treatment of uterine fibroids (20, 21), endometriosis (22), 
improved bleeding patterns in women using progesterone only contraceptives (23, 24) and 
optimizing in vitro fertilization treatment (25). Furthermore, the potential anti-tumor 
properties of mifepristone have been assessed in women with metastatic breast and ovarian 
cancer (26) and in our previous study from healthy human breast tissue in vivo, continuous 
administration of mifepristone suggested a protective effect on the human mammary gland 
(27). 
Mifepristone also binds to the glucocorticoid receptor (GR) in a dose dependent manner and 
with antiglucocorticoid effects occurring at continuous doses of 50 mg and single doses of 
>200 mg of the drug (28, 29). However, antiprogestin activity is apparent at much lower 
doses (29). The antiglucocorticoid effect of mifepristone has been explored in clinical trials 
for among others psychotic depression and to regulate hyperglycemia secondary to 
hypercortisolism in Cushing´s syndrome. For the latter indication, it is approved in the US 
since 2012 (Korlym®) with a recommended starting dosage of 300 mg/day (10). Mifepristone 
also binds to the androgen receptor (AR) to a lesser extent, but not to the mineralocorticoid or 
estrogen receptor (ER) (15). 
Mifepristone exhibits a quick oral absorption with peak serum concentration after 1-2 hours. 
In humans, mifepristone binds to a1-acid glycoprotein which regulates its serum kinetics and 
explains the low metabolic clearance rate. At intake up to 100 mg, distribution of 
mifepristone is linear, while at doses >100 mg a more rapid metabolization is seen. 
Mifepristone is further metabolized in the liver, by cytochrome P-450 enzyme CYP3A4, to 
mainly three metabolites, all maintaining considerable affinity to the PR. The elimination 
half-life of mifepristone is 24-48 hours measured with high performance liquid 
 
14 
chromatography, while other methods of measurement report a longer half-time of 54-90 
hours probably due to the presence of its metabolites. (30).  
1.3 LEVONORGESTREL INTRAUTERINE SYSTEM  
Levonorgestrel is a potent progestin acting as a full agonist of the PR. The levonorgestrel 
intrauterine system (LNG-IUS), with a 52 mg LNG reservoir, is a safe and highly effective 
long-acting reversible contraceptive (LARC) (31). The initial LNG release rate is 
approximately 20 µg per day which gradually decreases to 10 µg per day after 5 years, with 
plasma hormonal levels much lower compared to other non-intrauterine progestin-only 
preparations (32). Hence, the primary contraceptive effect of the device is not the suppression 
of ovulation which needs higher serum levels to be achieved; LNG-IUS thickens the cervical 
mucus which impairs sperm migration and function (33, 34). Furthermore, LNG-IUS 
represses the endometrium, reduces menstrual blood flow and approximately 50% of women 
become amenorrhoic during its use (31, 32, 35). In addition, it represents one of the best 
accepted and most cost-effective contraceptive methods available and also provides 
numerous non-contraceptive benefits in women with heavy menstrual bleeding, adenomyosis, 
endometriosis, but also protection and treatment of endometrial hyperplasia and possibly 
early endometrial cancer (32). The characteristic endometrial morphology during use of the 
LNG-IUS consists of decidualized stroma, marked endometrial atrophy and inactivity of 
endometrial glands as well as alterations in vascular morphology such as suppression of spiral 
artery formation and large, thin walled, dilated vessels (36, 37).  
Despite studies showing that the device can reduce overall menstrual blood loss by up to 97% 
after the first year of use (38), 25-62% of women experience initial unscheduled vaginal 
bleeding after the placement of the device, which constitutes one of the main reasons for the 
premature cessation of treatment (39, 40). Quite recently, two new lower dosed intrauterine 
systems with 19.5 and 13.5 mg levonorgestrel respectively in their reservoir, have been 










Figure 3. Levonorgestrel releasing intrauterine system with a 52 mg hormone reservoir. 
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1.4 BLEEDING IRREGULARITIES IN PROGESTIN ONLY CONTRACEPTIVE 
USERS 
Progestin-only methods of contraception include oral preparations, intrauterine systems, 
injectables, subdermal implants and vaginal rings. A universal major drawback with the 
continuous progestin-only preparations is the bleeding irregularities induced in a significant 
number of users even though the extent of the problem is likely influenced by the dose and 
type of the progestin, the mode of delivery and resulting effects on follicular development 
and ovulation as well as their specific endometrial affinity/effects (41). Nevertheless, 
undesired bleeding patterns constitute one of the main reasons for discontinuation of these 
methods (42). The underlying mechanisms responsible for the bleeding irregularities remain 
largely unknown and seem to be multifactorial with evidence pointing towards superficial 
blood vessel fragility and alterations in their density, but also local changes in endometrial 
steroid response, structural integrity, tissue perfusion and local angiogenic factors (42, 43). A 
rise in cytokines and prostaglandins have been shown in the endometrium during initial use 
of the LNG-IUS (36). In addition, alterations in expression of vascular endothelial growth 
factors (VEGF) as well as their receptors were demonstrated in women with LNG-IUS and 
bleeding disturbances initiated after a problem-free period of use, suggesting fragile and 
dysfunctional blood vessel formation (44). It could though be hypothesized that initial 
bleeding irregularities with LNG-IUS and bleeding irregularities/disturbances that appear 
after an untroubled period of use, are due to different underlying mechanisms and necessitate 
therefore different treatment approaches (45).  
Several pharmacological interventions have been tested with the intention to minimize the 
bleeding irregularities in progestin-only users and consequently increase patient satisfaction 
and reduce premature discontinuation of treatment. These interventions include non-steroidal 
anti-inflammatory drugs (NSAIDs), estrogens, progestins, vitamins, antifibrinolytic agents, 
matrix metalloproteinase inhibitors (doxycycline), the selective estrogen receptor modulator 
(SERM) tamoxifen and PRMs, either in single or combined regimens (41, 42). Despite these 
efforts there is up to date no effective treatment resolving the underlying problem in the long- 
term (42).  
Recently a new progestin-only pill (POP) 24/4 regimen has been introduced for drospirenone 
mid dosed pills, with the aim to induce more regular withdrawal bleedings. Despite improved 
bleeding pattern compared with continuous POPs, irregular and unpredictable bleeding is still 
common (46). Apart from the addition of a combined hormonal method there is so far, no 
cure. 
1.5 PROGESTERONE RECEPTOR MODULATORS AND CLINICAL 
APPLICATIONS IN REPRODUCTIVE MEDICINE 
1.5.1 Medical abortion 
Mifepristone is the only PRM approved for termination of pregnancy (15). It is licensed as a 
single dose treatment followed by misoprostol or gameprost, prostaglandin E1 analogues, for 
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medical abortion in over 60 countries worldwide (1, 15). The combination regimen of 
mifepristone and misoprostol is included in the List of Essential Medicines by the World 
Health Organization (WHO). 
1.5.2 Emergency contraception 
Emergency contraception (EC) is defined as any method utilized following intercourse to 
prevent pregnancy. It is an important strategy to prevent unintended pregnancy. Several 
pharmacological approaches have been described and utilized; initially administration of high 
doses of combined oral contraceptives (COC) - LNG/ethinyl estradiol (EE), the Yuzpe 
regimen, followed by LNG-only administration and later PRMs in a single dose regimen (47, 
48). In contrast to LNG-EC with a narrower window of action up to the start of increase in 
LH, PRMs inhibit the LH surge even after its onset. PRMs block follicular rupture likely by 
direct inhibition of follicular PR-depended pathways (49). PRMs are associated with fewer 
pregnancies than LNG-EC, with comparable side effects (18) when used up to 120 hours 
after intercourse (48). The mechanism of the antiovulatory effect of PRMs seems to be 
multifactorial and complex involving effects on the hypothalamic pituitary axis, the 
preovulatory increase in progesterone but also direct inhibition of follicular development and 
rupture as suggested recently for UPA (49, 50). Mifepristone was the first PRM to be used for 
EC purposes (51) followed by UPA (48). Despite mifepristone’s proven efficacy as an EC, it 
is today licensed on this indication only in China, Vietnam, Armenia, Moldova, Russia and 
Ukraine (10 mg, 12,5 mg, 25 mg and 50 mg respectively) while UPA is licensed in 
approximately 80 countries worldwide (30 mg) (52). 
1.5.3 Contraception 
Existing hormonal contraceptive methods include COC (estrogens plus a progestin), which 
are associated with increased risk of venous thromboembolism (VTE) but a very stable 
bleeding pattern (at least with EE), and progestin-only preparations which are not associated 
with an increased risk of VTE but are reported to have discontinuation rates up to 30% due to 
irregular and unpredictable bleeding patterns (53). Both methods are associated with 
suppression of ovulation in addition to reduced dysmenorrhea and blood flow. Since PRMs 
are proven to block follicular development and ovulation, and/or inhibit endometrial 
receptivity, they were very early predicted as potential novel long-term estrogen-free 
contraceptives with favorable bleeding patterns (54). A number of studies have explored 
these potential contraceptive effects of PRMs using different compounds, doses, routes of 
administration and regimens but up to date, no PRM is approved for regular contraception.  
A proof of concept study showed the potential of mifepristone as a regular contraceptive 
method. A once a month administration of 200mg of mifepristone immediately postovulatory 
on LH+2, resulted in a non-receptive endometrium that prevented implantation. Since 
ovulation was not affected, serum estrogen and progesterone levels remained unaltered and 
menstrual bleeding remained cyclic and regular (55). In contrast, continuous low doses 
interfering with ovulation results in amenorrhea in a dose dependent manner (19, 22).  
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The threshold for daily oral dose of mifepristone capable of inhibition of ovulation is 2 mg 
(19, 56) and that of UPA is 5-10 mg (57). Despite their effect on ovulation and follicular 
suppression, PRMs are proven not to be associated with hypoestrogenism during treatment 
(56-58).   
In a study exploring the contraceptive potential of lower continuous doses of mifepristone, no 
pregnancies occurred after 200 months of exposure to 2 mg or 5 mg daily in 50 women (19). 
Another study reported no pregnancies after 456 months of exposure to either 25 or 50 mg of 
mifepristone administered weekly, even though the weekly dose of 25 mg did not exhibit a 
consistent inhibition of ovulation but interfered with endometrial development (59). These 
data are in line with another study assessing the effect of continuous daily mifepristone dose 
of 1 mg, 5 mg or 10 mg. Even though the duration of the study was short (30 days), the group 
reported an inconsistent suppression of ovulation with 1 mg/day while treatment with 5 mg or 
10 mg was associated with a coherent ovulation blockage. However, endometrial maturation 
was disturbed by all doses which implicates a differential effect threshold of the follicle and 
the endometrium by mifepristone (58).  
Population Council conducted a dose finding study with a contraceptive vaginal ring 
delivering UPA and presented promising results (60). In a proof of principle study in rhesus 
macaques, a UPA impregnated intrauterine device induced endometrial atrophy and 
amenorrhea (61). The effects of PRMs delivered through an intrauterine device was also 
investigated in a small human study (62).   
Based on available data from various studies, PRMs hold the potential to be utilized as 
estrogen-free long-term contraceptives without estrogen deprivation and with stable bleeding 
patterns.   
1.5.4 Treatment of abnormal uterine bleeding 
Abnormal uterine bleeding (AUB) is a common condition that can affect up to 25% of 
women during their reproductive life (63). Common causes of AUB include uterine fibroids 
and endometrial polyps, adenomyosis, malignancy and premalignant lesions as well as 
coagulopathies, ovulatory dysfunction and iatrogenic causes such as various types of 
progestin preparations for contraceptive purposes. Bleeding due to iatrogenic causes is 
commonly termed ‘breakthrough bleeding’ (64). While some of the above mentioned 
structural causes of AUB require surgical intervention, many are hormonally mediated and 
can therefore be subjected to medical treatments. PRMs hold great potential for medical 
treatment of these conditions.   
Despite the differences in various PRMs, a common clinical feature in all is the large 
proportion of women who become amenorrhoic during continuous treatment, with the effect 
depending on dose and treatment duration. It seems that amenorrhea induced by PRMs is not 
only dependent on ovulation blockage (19). Some investigations suggest as contributing 
factors, downregulation of stromal growth factors (65), direct effect on endometrial blood 
vessels and in women with uterine leiomyomas, a moderate reduction in uterine artery blood 
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flow (1, 66). Furthermore, some studies have shown an amelioration of symptoms in women 
experiencing breakthrough bleeding following treatment with progestin only preparations as 
discussed in detail later in this thesis. In summary, the mechanism of amenorrhea following 
treatment with these compounds is poorly understood and more in vivo human studies are 
needed.  
1.5.5 Uterine leiomyomas 
High concentrations of ER and PR are expressed in leiomyoma cells relative to the adjacent 
myometrium and exposure to estrogen and progesterone promote leiomyoma growth (8). 
Therefore, treatment with PRMs have been evaluated for reduction of myoma size and as 
treatment of associated excess bleeding without estrogen deprivation. Mifepristone was the 
first PRM evaluated in clinical trials and later more studies with other PRMs also revealed a 
dramatic reduction in excess uterine bleeding and reduction in fibroid volume (20, 28, 67). 
Studies with UPA showed similar effects which resulted in the authorization of UPA as a 
treatment for moderate to severe symptoms of uterine fibroids (68, 69). The mechanisms 
contributing to leiomyoma growth reduction are not well elucidated. However, ample 
evidence from in vitro studies have shown that PRM induce apoptosis in leiomyomas through 
related pathways (70). In addition, PRMs can suppress collagen synthesis through modulation 
of extracellular matrix (ECM) enzymes like metalloproteinases (MMPs) (71). Long-term 
treatment with PRMs induce specific endometrial changes, now named ‘PRM associated 
endometrial changes’ (PAEC). Due to these changes and the lack of evidence regarding long 
term endometrial safety in their presence, the initial authorization was for preoperative 
treatment only (3 months).  Following studies with UPA were designed to assess endometrial 
safety with regards to presence of PAEC which eventually led to authorization for 
intermittent long-term therapy but with endometrial shedding between treatment courses of 
three months (72, 73). It should be noted that the indication for the latter got suspended in 
March 2020 during ongoing review of liver injury risk and as per November 2020 restricted. 
Research on the use of other PRMs for the treatment of uterine fibroids are on hold. 
Currently, the Committee for Medicinal Products for Human Use of the European Medicines 
Agency has recommended the European Commission to re-approve UPA for intermittent use 
for moderate to severe symptoms of fibroids but with stricter indications. This issue is further 
discussed in section 5.  
1.5.6 Endometriosis 
Endometriosis is a common disease with a pathogenic complexity that still remains unclear. It 
is defined as the presence of endometrial glands and stroma in ectopic locations and it is 
mainly considered an estrogen-dependent condition. The medical treatment of the disease is 
currently dominated by agents that suppress the pituitary-ovarian axis and induce endometrial 
atrophy. Common medical treatments for endometriosis includes COCs, progestins or 
gonadotropin-releasing hormone agonists. The latter induce estrogen depletion with 
consequent adverse effects of vasomotor symptoms, urogenital tract symptoms and bone 
mass loss (65).  
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Considering PRMs in endometriosis therapy, concerns were raised regarding the difficulty to 
predict the effect of PRMs since the ectopic endometriotic tissue presents different steroid 
metabolism and enzyme physiology compared to the eutopic endometrium (8). Nevertheless, 
PRMs have shown a reduction of endometriotic lesions in animal models, and small studies 
in women utilizing 50 mg mifepristone daily for six months, indicated significant beneficial 
effects on symptoms and extent of the disease (22, 65). Several explanations have been 
offered to account for these observations including anovulation, suppression of menstruation, 
inhibition of endometrial proliferation, apoptotic effects and suppression of endometrial 
prostaglandin production with subsequent pain relief (8, 65). Even though PRMs appear to be 
promising for the treatment of endometriosis with the benefit of avoiding hypoestrogenism 
(56, 58), more studies are clearly needed for this indication. This will also include long-term 
follow up to define the specific role of PAEC that may develop in the ectopic lesions as 
observed in the eutopic endometrium described below. 
1.6 PROGESTERONE RECEPTOR MODULATOR ASSOCIATED 
ENDOMETRIAL CHANGES (PAEC) 
Since various PRMs have mixed or full antagonistic effect on the PR, concerns were raised 
on whether long-term administration of this group of compounds could induce endometrial 
alterations as in unopposed estrogen exposure. Lack of endometrial progesterone protection 
would result in actively proliferative appearances as seen in disordered proliferative 
endometrium or endometrial hyperplasia (74). Although early studies reported morphological 
endometrial changes described as glandular hyperplasia after long-term administration of 
PRMs, these changes were later, in 2008, widely recognized as PAEC – a distinct histological 
entity (75).  
Trials have shown PAEC rates of close to 60% following repeated courses of UPA (72). The 
common and most prominent histologic features of PAEC include cystic dilatation of 
endometrial glands, irregular architecture lined by inactive gland cells and compact, non-
decidualized stroma. Interestingly, none of these features are unique when occurring 
separately, but their combination does not occur in physiological states even though they 
have rarely been described in patients not treated with PRMs (74). While there is evidence 
that all family members of PRMs induce these histological changes, the characteristic 
features are varying, depending on the PRM used (37). Further features include vascular 
changes such as prominent but delicate anastomosing capillary networks but also thick walled 
vessels (75). PAEC have been proven to be reversible to a great extent following cessation of 
therapy and shedding of the endometrium. Therefore, treatment with UPA to decrease uterine 
fibroid volume was initially restricted to a 3-month treatment (68, 69). Since the development 
of PAEC was initially thought to be the consequence of unopposed estrogen action, a later 
study was designed to separate each 3-month course of UPA by a sequence of progestin 
(noretisterone acetate) to limit the development of PAEC. However, this regimen could not 
demonstrate prevention of occurrence, or induce faster resolution of PAEC (72), resulting in 
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the clinical treatment recommendations where intermittent courses with UPA were separated 
by two menstrual cycles (48, 73).  
While PAEC are now well described, appear reversible and are considered to be benign due 
to the lack of cytological atypia (75), the mechanism by which they develop and their 
significance is still unknown (2, 74). More evidence is required to define if these changes 
persist over time, dissolve or progress after PRM exposure and why PAEC do not develop in 










Figure 4. Endometrial biopsy (not from our study) to illustrate PRM-associated endometrial changes (PAEC). 
Endometrial glands show cystic dilatation, some with distortion of architecture. Glandular epithelial lining is 
inactive but not atrophic, and there is non-physiological secretion. The stroma is compact and non-decidualized. 










Figure 5. Endometrium showing progestin effect (not from our study). Some glands show cystic dilatation, and 
glandular epithelium is flattened and atrophic. The stroma shows confluent decidual change. Image courtesy: 




1.7.1 Development, homeostasis and risk factors 
Breast development starts during fetal life and undergoes dramatic changes during women’s 
life, with the major changes occurring at puberty, pregnancy, lactation and in the postpartum 
period. The breast tissue is also susceptible to proliferation, differentiation, and involution 
(regression) with every menstrual cycle, orchestrated by fluctuations of the ovarian hormones 
estrogen and progesterone. Later in life, during the time of menopause, the breast undergoes 
involution, where epithelium is gradually replaced by adipose tissue. Full differentiation and 
maturation of the breast tissue is considered complete after the first full term pregnancy (76).   
 
Figure 6. Schematic illustration of the female breast anatomy. Image courtesy: Wikimedia Commons, 
illustration by ©Patrick J. Lynch. 
The mammary gland consists mainly of epithelium and stroma (inter- and intralobular), the 
latter comprised of adipose tissue, fibroblasts, extracellular matrix and immune as well as 
hematopoietic cells. Development and homeostasis of the breast are coordinated by complex 
reciprocal interactions between the different cell lineages and their microenvironment, 
accompanied by growth factors and cytokines (77).The granular tissue corresponds to a 
minor compartment in the breast and consists of 15-25 ducts, each giving rise to a lobe 
arranged in a branching system which ends in several terminal ductal-lobular units (TDLUs). 
The TDLUs are surrounded by the intralobular stroma and are the functional units of the 






Figure 7. Schematic illustration of the terminal ductal-lobular unit (TDLU). Adapted from Dimri, Breast Cancer 
Research, 2005. 
Initially, breast cancer was considered a cancer form of nuns, who may have led a healthy life 
but had an uncommon reproductive behavior. Epidemiological studies revealed a number of 
risk factors which solely or combined, seem to increase breast cancer susceptibility. The 
majority of those are positively correlated to the number of menstrual cycles a woman 
undergoes during her lifetime and thus the cyclic exposure time of the breast to ovarian 
hormones (79). However, the biological mechanisms of breast cancer susceptibility linked to 
the fluctuation of the ovarian hormones are not well understood. The mid-luteal phase of the 
menstrual cycle, where levels of estrogen reach a smaller peak and progesterone levels are 
high, is the proliferative phase in the mammary gland whilst during the late luteal phase the 
breast epithelium undergoes apoptosis and tissue remodeling (77). Even though the role of 
progesterone in the breast has been debated for many years, a growing body of literature 
suggests that the mitotic and subsequent apoptotic activity of the glandular tissue is 
associated with progesterone’s rise and withdrawal during one menstrual cycle under the 
influence of estrogen. There is also a positive correlation between levels of serum 
progesterone and mitotic activity in the breast reflected by a higher level of mitotic activity 
assessed by cellular expression levels of the proliferation marker Ki67 (80, 81). Mitotic 
activity increases the risk of genomic instability, due to the risk of random genetic errors 
during DNA replication, and consequently the risk of tumorigenesis. In addition, estrogen 
induces proliferative effects in the breast by direct binding to the ER but is also responsible 
for upregulation of the PR during the luteal phase (77). Altogether, data supports that 
progesterone exerts proliferative effects in the mammary epithelium which is in sharp 














Figure 8. Ovarian and pituitary hormone fluctuations during one menstrual cycle together with tissue changes in 
the ovaries, uterus and breast. Notably, with regards to changes in tissue structure, the proliferative phase during 
the follicular phase corresponds to the uterus (endometrium) whilst the proliferative phase in the luteal phase of 
the cycle corresponds to the breast. Modified from Brisken, Nature Reviews, 2013. 
Large observational studies conducted in postmenopausal women have linked use of 
menopausal hormone therapy to an increased risk of breast cancer when estrogen is combined 
with progestins (82, 83) and in particular when the progestin intake was on a daily basis 
rather than intermittently (84). Similarly, the effect of hormonal contraception in 
premenopausal women seems to slightly increase the risk of breast cancer in current users 
(85, 86). 
Other factors associated with breast cancer risk include age, extensive breast density visible 
on mammogram, heredity and other genetic factors, personal history of breast pathologies, 
socioeconomic group and geographical location, life style factors and environmental 
exposures (86). Another parameter consistently associated with increased breast cancer risk is 
obesity. Interestingly, while population based studies demonstrate a positive association 
between obesity and postmenopausal breast cancer, the association in premenopausal women 
seems to be inverse, with fewer ovulatory cycles suggested as a plausible explanation (86, 
87). 
Despite decades of research and rapid advances in molecular diagnostics, breast cancer is still 
the most frequent female malignancy and a major health concern worldwide. It is estimated 
that approximately 276.480 new cases of invasive breast cancer and 48.530 new cases of 
adenocarcinoma in situ will be diagnosed in the US year 2020. The incidence rates show a 
slight increase in recent years (by approximately 0.3%/year) (88). Our efforts to treat but 
most importantly prevent breast cancer, are significantly hampered by our knowledge gaps in 
biology and developmental genetics of the healthy breast.  
 
24 
Table 2. Risk factors of breast cancer. Adapted from Veronesi, Lancet, 2005. 
 
Relative risk High-risk group 
Age > 10 Elderly 
Geographical location 5 Developed countries 
Breast density > 5 Extensive dense breast 
Age at menarche 3 Before age 11 
Age at menopause 2 After age 54 
Age at first full pregnancy 3 First child after age 40 
Family history ≥ 2 BC in first-degree relative 
Previous benign breast disease 4-5 Atypical hyperplasia 
Cancer in other breast > 4 Previous breast cancer 
Socioeconomic group 2 High and low 







Alcohol consumption 1.07 7 % increase with every 
daily drink 
Exposure to ionising radiation 3 Abnormal exposure to 
young girls after age 10 
Breastfeeding and parity RR falls by 4.3 % for every 
12 months of breastfeeding 
in addition to a 7 % 
reduction for every birth 








BC=breast cancer, BMI=body mass index, RR=relative risk, MHT=menopausal hormone therapy.  
1.7.2 PR expression, distribution and paracrine mechanisms 
The majority of our knowledge on how different factors of interest impact the breast tissue, 
have been assessed by markers of proliferation or apoptosis, evaluated by 
immunohistochemistry or immunocytochemistry. Although these methods have been useful, 
they cannot delineate the complex interplay within the mammary gland. The steroid hormone 
receptor expression and distribution in the normal breast have therefore been studied. Normal 
breast of premenopausal women seems to exhibit a sparse overall distribution of ER and PR, 
with PR detected in about 20% of luminal cells (89). There is though, a great heterogeneity in 
the distribution of receptor staining even within the same tissue sample, depending on the 
examined section, adding even more to the complexity of breast tissue assessment (90). 
Nevertheless, immunohistochemical staining in cryostat or paraffin sections from women 
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biopsied due to mainly fibroadenomas, showed staining predominantly in the TDLU and 
while the proportion of PR positive cells was unaffected with OC pill use, the intensity of PR 
detection increased (90). Furthermore, not only the ER but also the proportion of PR 
expression was significantly decreased in the breast tissue of healthy women treated with the 
SERM tamoxifen (91). With more advanced technologies, some studies could show a 
reduced expression level of PR mRNA transcripts in parous women compared to nulliparous, 
a relation that have been postulated to contribute to the protective effect of full-term 
pregnancy regarding breast cancer risk (92).  
As previously discussed, there are mainly two isoforms of PR, namely PR-A and PR-B. 
While animal and in vitro data have demonstrated different actions of the two isoforms in 
various developmental stages of the mammary gland, the in vivo actions in humans still 
remain unclear. In addition, concerns have been raised regarding our ability to reliably 
distinguish the two isoforms from each other. While the differentiation between the two 
isoforms seems to be consistent by western blot due to their difference in size, their similarity 
in structure have made it difficult to distinguish them by immunohistochemical methods. The 
antibodies used have been proven not be as selective as anticipated (93).  
Recently, studies in mice have shown that PR activation of luminal breast epithelial cells 
drives proliferation in adjacent PR negative cells through paracrine mechanisms, with 
receptor activator of nuclear factor kappa-B ligand (RANKL) being an important paracrine 
mediator (94). This has gained immediate interest, not the least due to the existence of an 
antibody already in clinical use (denosumab) licensed for treatment of patients with different 
bone disorders. Denosumab binds to RANKL and inhibits its downstream receptor activation. 
A small study reported detection of RANKL expression, assessed by immunohistochemistry, 
in reduction mammoplasty specimens in women who displayed high serum progesterone 
levels at the time of the surgery. In the same study, expression of the RANKL protein could 
not be detected in women with low serum progesterone levels (95). Larger studies are needed 
to prove this pathway to be consistently involved in humans and breast carcinogenesis. This 
could pave the way for new treatment modalities in breast cancer patients as well as new risk 
reduction strategies not least in women with high breast cancer susceptibility.    
1.7.3 Mifepristone effects in the breast 
In the clinical setting, apart from the histological classification and grade of breast cancers, 
large genomic analyses have helped to introduce the molecular classification of these 
malignancies (96). This molecular classification is today mainly based on expression levels of 
ER, PR and HER2 and divided into 4 main subtypes that guide therapy and predict prognosis 
(96, 97). Even if this classification provides a very important framework, it is far from 
perfect. New information is constantly being added with the help of high-throughput 
technologies. In addition, expression of ER and PR is measured by immunohistochemistry. 
This per se, introduce errors in the assessment. It is a semi-quantitative method using a low 
cut off for positive scoring (1-10%) (98) and not all antibodies detect steroid receptor 
isoforms equally (97). It has further been suggested that loss of protein expression could 
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merely reflect its rapid degradation and that loss of its expression is difficult to interpret when 
mRNA is present or not measured in each and every patient (97). 
The epidemiological studies linking ovarian steroid hormones to increased breast cancer risk 
provided the rationale for a series of approaches investigating the potential beneficial effects 
of ER and PR antagonism. The first study assessing the effect of mifepristone was conducted 
in breast cancer cell lines and the group reported a dose dependent growth inhibition of the 
PR+ cell lines (99). Thereafter, a number of in vitro studies demonstrated similar effects, with 
outcomes depending on the dose, the cancer cell lines used and the expression levels of the 
PR (26). Studies in rodents have also shown inhibition of growth rates of mammary tumors, 
and other PRMs have exerted similar effects, in particular those with marked PR antagonistic 
activity (26, 100). In small studies including patients with metastatic breast cancer and failed 
third- or fourth-line endocrine therapy, mifepristone has shown partial responses and it has 
been suggested that mifepristone may be useful in combined therapies in this patient group 
(100). 
In terms of breast cancer prevention, there is only one previous study examining the effects of 
mifepristone on the human healthy breast tissue in vivo, showing an inhibition of breast 
epithelial proliferation and hence a possible protective effect (27). This potential protective 
effect of PRMs in the breast is of great interest in addition to their other therapeutic properties 
in particular when used long term in current or future indications. 
1.8 BRCA 
The vast majority of breast and ovarian cancer cases are sporadic but approximately 7-10% of 
these malignancies are hereditary and estimated to be due to breast cancer susceptibility 
genes. BRCA1 and BRCA2 are the two major susceptibility genes and mutations in these 
tumor suppressor genes account for a life time risk of developing breast cancer by 54-85% 
and 45% respectively (101). There is no single management strategy in reducing the risk of 
breast and ovarian cancer for BRCA mutation carriers and hence various risk reducing 
strategies such as surveillance, risk reducing surgery and chemoprevention are utilized, 
making the clinical management of these individuals very complex and challenging (102, 
103).  
Until to date, we have no answers regarding the organ-specific caner penetrance of these 
mutations (97). Quite recently, a study conducted in BRCA1/2 carriers, reported 121% and 
33% higher progesterone and estradiol serum levels respectively, in the luteal phase 
compared to women with no mutations (104).  These higher exposures may be a possible link 
to the increased breast cancer susceptibility in the mutation carriers. In an animal model of 
BRCA1 mutation utilizing BRCA1/p53-deficient mice, treatment with mifepristone 
prevented mammary tumor development (105). As described, we have previously shown an 
antiproliferative effect of low dose mifepristone in human breast tissue in vivo (27). Thus, a 
protective effect of PRMs in breast tissue could be hypothesized providing an additional 
plausible non-invasive risk-reduction strategy in women with increased risk of breast cancer.  
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2 AIM AND OBJECTIVES 
 
The overall aim of this thesis is to explore the effects of the progesterone receptor modulator 
mifepristone on the endometrium and on human breast tissue in premenopausal women.  
The specific objectives of each study were as follows:  
Study I: To assess the effect of pretreatment with mifepristone on the bleeding pattern after 
placement of the LNG-IUS for contraceptive purposes. 
Study II: To evaluate the endometrial morphology including presence of PAEC in 
mifepristone primed endometrium followed by placement of the LNG-IUS with no prior 
endometrial shedding. 
Study III: To explore the molecular responses associated with progesterone receptor 
antagonism in breast tissue in vivo of healthy premenopausal women.  
Study IV: To investigate the effect of PRMs on genetic and epigenetic surrogate markers for 





















3 MATERIALS AND METHODS 
A comprehensive overview of materials and methods are explained in this section. More 
details are provided in Study I-IV articles and manuscripts.   
3.1 TABULATED OVERVIEW OF STUDIES 
 
Table 3. Overview of study designs, participants, methods and statistics. 
Study  Design and participants Outcome Participants 
contributing to 
final analysis 
Method Data analysis 
I 
Effect on bleeding 
pattern following 
treatment with 
continuous low dose 
mifepristone prior to 
LNG-IUS insertion  
Randomized double-
blind placebo controlled 
trial 
Healthy women opting 
for a LNG-IUS for 
contraception, age 18-43 
Rate of bleeding 
and spotting days 
reported during 3 







Daily diary of 
vaginal bleeding 
and adverse effects 
Transvaginal 
ultrasonography + 
blood samples for 













with mifepristone and 
immediate placement 
of a LNG-IUS   
Secondary outcome of 
RCT 
Endometrial biopsies at 
baseline, followed by a 
2-month mifepristone 
treatment, LNG-IUS 
placement and second 
biopsy after 3 months 
with the device in situ  




presence of PAEC 







shedding    
Secondary 
outcome Study I 
Mifepristone   
n=9 

















treatment in healthy 
premenopausal breast 
tissue in vivo  
Secondary outcome of 
RCT 
Breast biopsies from 
healthy premenopausal 
women before and after 
a 2-month treatment with 
mifepristone  
Healthy women from 
trial I 
Alterations of the 
transcriptomic 

























in breast following 
PRM treatment and 
assessed by surrogate 
markers  
Experimental, hypothesis 
generating study. Patient 
cohorts from Study I, 
BRCA RCT and 







breast cancer  
Study I:            
M:  n=9, C: n=11 
BRCA trial:      
M: n=11, C: n=4 
UPA trial:       
n=9 
Establishment and 
validation of a 
breast specific 
epigenetic index, 
then used to assess 
the patient cohorts   
Non-paired sample 









3.2 STUDY DESIGN 
3.2.1 Study I, II and III 
This thesis is mainly based on data from a prospective, randomized, placebo controlled, 
double-blind trial that we conducted at the Karolinska University Hospital, Stockholm, 
Sweden. The study was designed to assess the effect of pretreatment with the progesterone 
receptor modulator mifepristone on bleeding patterns, following placement of a LNG-IUS   
52 mg for contraceptive purposes (study I). A total of 68 healthy women opting for a LNG-
IUS were assessed for eligibility and 58 were randomized. The first participant was screened 
in November 2009 and the last screened in in November 2013, with the final study contact in 
January 2015.  
A secondary objective of the trial, presented in study II, was to delineate the endometrial 
morphology in women using the LNG-IUS in the mifepristone primed endometrium. Further, 
to assess the presence of progesterone receptor modulator associated endometrial changes 
(PAEC) with this combined treatment regimen, with no endometrial shedding prior to the 
insertion of the device. 
Another secondary objective of the trial, presented in study III, was to explore the molecular 
alterations in breast tissue in vivo, following treatment with mifepristone.  
3.2.2 Timeline of intervention and data collection events 
 
 
Figure 9. Schematic timeline presentation of the trial resulting in study I-III. The mifepristone pretreatment 
period corresponds to months 1 and 2 in the timeline, followed by the LNG-IUS insertion. The first 3 months 
contributing to the bleeding data analysis for Study I corresponds to months 3-5 in the timeline. The endometrial 
biopsy at baseline and 3 months after placement of the IUD was assessed in Study II. Breast biopsies, at baseline 
and at the end of the pretreatment period were assessed in Study III and were also part of Study IV. 
 
 31 
3.2.3 Study IV 
This was a hypothesis generating experimental study including several patient cohorts of 
healthy women (unknown BRCA status), women with known BRCA mutation and women 
with high risk for developing breast cancer. One cohort consisted of BRCA mutation carriers 
and confirmed non-carriers for assessment of sex steroid hormones measured in saliva. A 
DNA methylation signature surrogate for replicative age, named WID-Brest29 index, was 
established and validated using data sets from breast tissue of BRCA 1 and 2 mutation 
carriers, healthy controls, and triple negative breast cancer (TNBC) patients. Thereafter, the 
impact of mifepristone was assessed using the WID-Breast29 index using 2 cohorts. The first 
cohort consisted of women from study I. The second cohort included women with BRCA 1 
or 2 mutations, participating in another RCT conducted at the Karolinska university hospital, 
a prospective, randomized, placebo controlled, double-blind trial assessing the effect of 
mifepristone, 3 months treatment, versus a comparator on the breast. An additional third 
cohort was included to assess the impact of UPA on breast tissue in women with increased 
risk for breast cancer. These women are also from an ongoing RCT conducted in Manchester, 
UK. Finally, the impact of mifepristone on TP53 mutations was evaluated in women deemed 
to respond to mifepristone based on the reduction in WID-Breast29 index. 
3.3 STUDY SUBJECTS 
3.3.1 Study I, II and III 
Eligible women for the randomized controlled trial were healthy, ≥18 years of age with 
regular menstrual cycles, opting for a LNG-IUS 52 mg for contraception. Table 4 explains in 
detail the inclusion respectively exclusion criteria for the trial.  
Table 4. Inclusion and exclusion criteria study I 
Inclusion criteria Healthy  
 Age ≥ 18 
 Request of LNG-IUS for contraception 
 Regular and normal menstrual cycles 25-35 days 
 Willing and able to participate after giving informed consent 
 Can and will use barrier methods for contraception during pretreatment 
period and + 7 days after the LNG-IUS insertion 
Exclusion criteria  Hormonal treatment or IUD use within 2 months prior to study start 
 Any contraindication for mifepristone or LNG-IUS  
 Pregnancy or breast feeding within 2 moths prior to study start  
 Current signs of pelvic inflammatory disease 
 Unexplained irregular vaginal bleeding  
 History of malignant disorder of the breast 
 History of other malignancies 
 Abnormal laboratory values at baseline 
 Abnormal gynecological ultrasound at baseline  
 Abnormal Pap smear findings at baseline 
Exclusion criteria for per 
protocol analysis 
Violation of the study protocol 
Lack of essential data 
LNG-IUS=levonorgestrel intrauterine system, IUD=intrauterine system 
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3.3.2 Study IV 
Saliva sample collection 
BRCA1/2 mutation carriers (n=12) and confirmed non-carriers (n=8) included for the saliva 
sample collection were recruited as part of the UK, BRCA Unite Research study 
(http://www.brcaunite.org). The inclusion criteria for women participating were: age 18-45 
years, no current pregnancy or breast feeding, hormonal medication 3 months prior to 
recruitment, previous cancer diagnosis or previous risk reducing bilateral salpingo-
oophorectomy.  
Breast samples/DNA methylation data sets  
The following cohorts/databases were used for the DNA methylation (DNAme) microarray 
analyses: 
1. To establish and validate the WID-Breast29 index:  
a. Breast tissue samples from healthy women (n=14) opting for cosmetic breast 
surgery. The participants had no family or personal history of breast cancer and 
the average age of the group at surgery was 31 years.  
b. Breast tissue from BRCA1/2 mutation carriers (n=14). The average age at breast 
surgery was 36 years.  
c. Breast tissue from TNBC patients (n=14). Tissue was collected from the tumor 
and from non-cancerous sites surrounding the tumor, in the same individual. The 
average age at breast surgery was 43 years. 
 
2. To assess the WID-Breast29 index in ER+/PR+ cancers:  
Breast tissue from ER+/PR+ stage T1-T2 breast cancers and from non-cancerous 
tissue surrounding the tumor, in the same individual (n=31). The average age at 
surgery was 51 years. These datasets were available from GEO  (Gene Expression 
Omnibus – a public functional genomics data repository) 
3. To assess the performance of the WID-Breast29 index for evaluation of mifepristone 
effects  
a. Part of the women from our trial (Study I) were included in this analysis. Nine 
samples from the mifepristone and 11 samples from the comparator group 
respectively, provided sufficient DNA in both biopsies (baseline and end of 
treatment) for the downstream analysis (extended data Figure 3, Study IV). 
b. Part of the women from our ongoing BRCA1/2 trial were included in this 
analysis. The ongoing study is a prospective, randomized, placebo controlled, 
double-blind trial in BRCA1 or 2 mutation carriers treated with mifepristone      
50 mg or the comparator Triobe® (as in Study I) every other day for 3 months. In 
brief, eligible women are 18 years or older, with regular menstrual cycles and no 
hormonal medication 2 months prior to reqruitment, not pregnanant, breastfeeding 
or with a history of malignancy. Core needle biopsies are collected at baseline and 
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at the end of treatment. Eleven women from the mifepristone and 4 women from 
the comparator group provided sufficient DNA in their paired biopsies for 
downstream analysis (extended data Figure 3, Study IV). 
 
4. To assess the performance of the WID-Breast29 index for evaluation of UPA effects.  
Women (n=9) with an increased risk of breast cancer who are part of an ongoing 
“Breast Cancer Anti-Progestin Prevention Study 1” conducted in the UK were 
included. This is a single arm pilot study designed to test the efficacy and safety 
of UPA in breast cancer prevention. Eligible are women at increased risk of breast 
cancer (≥1:6 lifetime risk assessed by Tyrer-Cuzick model version 8) and with 
regular menstrual cycles. A breast biopsy was retreived in the luteal phase of the 
menstrual cycle, and the second biopsy after treatment with UPA 5 mg daily, for 3 
months from the contralateral breast (extended data Figure 6, Study IV).  
Impact of mifepristone on TP53 mutations 
To assess whether Tumor Protein 53 (TP53) mutation frequency can be altered by 
mifepristone treatment, breast tissue from women deemed to respond (n=5) or not (n=3) to 
mifepristone based on the reduction in WID-Breast29 index, was evaluated. TP53 is a tumor 
suppressor and upon mutation, implicated in over 50% of human cancer and highly prevalent 
in TNBCs (106). TP53 has further been described in mutated form in a variety of normal 
tissues including breast (107). Eight samples were analyzed.  
3.4 METHODS STUDY I 
3.4.1 Randomization, study medication and interventions 
Women who were willing to participate and fulfilled all the inclusion and none of the 
exclusion criteria were randomized at a ratio of 1:1 in blocks of 10, by dispensing opaque 
identical, sequentially numbered pill packs prepared according to a computer-generated 
randomization list containing the allocation.  
The screening visit included detailed assessment of women’s medical and reproductive 
history, routine physical examination including blood pressure, height and weight 
measurements, gynecological examination including transvaginal ultrasound, breast palpation 
and pregnancy test. As a safety parameter, blood samples were collected at baseline and after 
the pre-treatment period (complete blood count, follicle-stimulating hormone (FSH), LH, 
prolactin, estradiol and progesterone).  
According to the allocation, women received mifepristone (Mifegyne®, Exelgyn, Paris, 
France) 200 mg or visually indistinguishable vitamin B (TrioBe®, Recip, Stockholm, 
Sweden). One TrioBe® tablet contains cyanocobalamin 0.5 mg (B12), folic acid 0.8 mg (B9) 
and pyridoxine hydrochloride 3 mg (B6). A study nurse, not participating in any other parts 
of the study, divided the tablets into 4 parts and instructed the women to take one quarter of 
the comparator or mifepristone (which equals to approximately 50 mg mifepristone) orally, 
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every other day starting on the first day of the menstrual cycle. The duration of the pre-
treatment period was 2 months, corresponding to two menstrual cycles (2x28 days) prior to 
the LNG-IUS (Mirena®, Bayer) insertion and until 3 days (±2 days) after the insertion. 
Following the pre-treatment period, pregnancy test and chlamydia samples as per clinical 
routine were taken and the LNG-IUS was placed. 
Endometrial biopsies were collected at baseline, prior to the pre-treatment period and three 
months after the LNG-IUS insertion, with the device in situ. The rationale and assessment of 
these biopsies are presented and further discussed in Study II.  
Breast biopsies were collected at baseline and at the end of the 2-month pre-treatment period. 
The rationale and evaluation of these biopsies are presented and further discussed in Study III 
and constitutes also part of Study IV.  
3.4.2 Bleeding diaries 
The study participants were instructed to keep daily diaries of vaginal bleeding during the 2-
month pre-treatment period and until 6 months after the LNG-IUS insertion. One treatment 
cycle corresponded to 28 days in the diary. Bleeding was graded on a five-point scale as none 
(0), spotting (1), mild (2, less than normal menstruation), moderate (3, similar to normal 
menstruation) or severe (4, heavier than normal menstruation). Women were also asked to 
keep records of adverse effects and potential concomitant medication during the same study 
period. The diaries were monitored at every visit by a study coordination midwife.  
The bleeding diary data were summarized as percentage rate of bleeding and spotting (B/S%) 
per treatment cycle (28 days) for comparison between the treatment groups. In the five-point 
scale provided, spotting, mild, moderate and severe bleeding was classified as a bleeding 
event (1+2+3+4 in the bleeding scale). A separate analysis was conducted to compare the 
proportion of women with normal or heavy intensity bleeding (3+4 in the bleeding scale).  
3.5 METHODS STUDY II 
3.5.1 Study participants 
The participants for study II originate from the randomized control trial (study I). Nine paired 
samples from the mifepristone and 8 paired samples from the comparator arm respectively, 
contributed to the final data analysis for the endometrial assessment. Paired samples implicate 
endometrial sample at baseline, prior to the pre-treatment and 3 months after the LNG-IUS 
placement, from the same woman. The two groups were comparable in terms of age, 
pregnancies, parity, menstrual characteristics and body mass index (BMI).  Flow chart and a 
detailed description of the demographic characteristics of the current cohort are available in 
the published article.   
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3.5.2 Endometrial biopsies 
The first endometrial biopsy was retrieved at baseline, prior to the pre-treatment with 
mifepristone or the comparator and the second one at 3 months after placement of the LNG-
IUS with the device in situ. The LNG-IUS placement was commenced directly after the 
pretreatment period, with no prior endometrial shedding. An endometrial disposable plastic 
suction curette was used for retrieval. One part of the biopsy was sent for routine pathological 
evaluation as a safety measure, while one part was fixed, sectioned, processed and stained 
with hematoxylin and eosin by standard methods and stored at +4°C.   
3.5.3 Histological assessment  
The stained samples were histologically assessed in Edinburgh, by an expert pathologist in 
the field of PAEC, who was blinded to the treatment. The evaluation was made according to 
1) primary diagnosis (benign, hyperplastic or malignant), 2) whether morphological 
appearances represented a physiological state or not and if physiological, record the stage of 
the menstrual cycle and 3) the presence or absence of PAEC. Free text comments were given 
if other histological features were present. 
3.6 METHODS STUDY III 
3.6.1 Study participants 
The participants contributing to the paired breast biopsies evaluated in study III derive from 
the enrolled subjects of the randomized controlled trial (study I). Only women from the 
mifepristone arm were included in the current cohort. Flow chart and a detailed description of 
the demographic characteristics of the cohort are available in the published article.   
3.6.2 Breast biopsies  
Core needle breast aspiration biopsies were collected by one radiologist at baseline, and at the 
end of the pretreatment period of 2 months (paired samples). Local anesthesia was applied in 
the skin to minimize patient discomfort. The specimens were collected under ultrasound 
guidance from the upper outer quadrant of one breast using a 14-gauge needle with an outer 
diameter of 2.2 mm. The collected breast tissue was divided into 2 parts, snap-frozen and 








3.6.3 General workflow of RNA-seq and data analysis 
 
 
Figure 10. General workflow of RNA-seq and data analysis used in this study. Following sample preparation 
and library generation, NGS reads were sequenced with the Illumina NextSeq 550® and subsequently aligned to 
the hg38 genome. Differential expression of read counts was analyzed using DEseq2. Gene Ontology (GO) and 
pathway analysis were performed to interpret the results. 
3.6.4 RNA extraction 
For the transcriptomic analysis, RNA extraction was performed from 16 randomly chosen 
paired breast samples (i.e. 32 samples) using whole tissue. Briefly, for the extraction, the 
PurelinkTM RNA Micro kit in conjunction with TRIzol® was used, in order to isolate the total 
RNA from the tissue samples. For purification of the total RNA retrieved, each sample was 
deoxyribonuclease (DNAse) treated to eliminate the contaminating genomic DNA. The final 
concentrations of the RNA samples (quantification) was done using the QubitTM RNA High 
Sensitivity Assay Kit.  
3.6.5 cDNA library construction and sequencing 
cDNA libraries for next generation sequencing (NGS) were constructed using 1 ng RNA each 
for the 16 paired samples, using the well-established Smart-seq2® protocol (108). NGS 
library construction was done based on the QubitTM quantification. Tagmentation of the 
cDNA was performed using Nextera® XT Kit (Illumina®) followed by addition of adapters 
and index primers. The resulting DNA libraries after Nextera® reactions were purified using 
AMPure XP beads (Beckman Coulter, USA) and quantified (Qubit flexTM, Life 
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technologies). 10 ng of DNA from each post Nextera library was pooled and sequenced on 
Illumina NextSeq 550® instrument using 1x75 cycles High output kit at the Bioinformatics 
and Expression Analysis Core facility, Karolinska Institutet, Stockholm. 
3.6.6 RNA-seq data processing and analysis 
Quality check of raw sequencing reads was performed with FastQC and MultiQC (109). 
RNA sequencing data analysis was performed with the Partek® Flow® Genomic Analysis 
Software (Partek Inc., St. Louis, Missouri, USA). Briefly, the FASTQ files were processed to 
filter the contaminants such as ribosomal DNA and mitochondrial DNA using Bowtie 2 
aligner followed by trimming the standard Nextera Transposase adapter 
(CTGTCTCTTATACACATCT) from the raw reads. The filtered reads were then aligned to 
the hg38 genome using STAR aligner with default settings. Total alignment rate was in the 
range of 95-99% of which the unique alignment rate was 80-92% with an average Phred 
quality score of 34 per base post alignment. The filtered alignments were quantified to hg38 
Ensembl Transcripts release 100. The obtained gene features were filtered off where the 
value was less than 1 count in at least 80% samples. A total of 26.581 (78%) genes passed the 
criteria. Differential expression analysis was performed using DEseq2 on the Partek platform. 
3.6.7 Gene Ontology and pathway analysis 
For interpretation of the differentially expressed genes (DEGs) in our data set, we conducted 
functional annotation and pathway gene set enrichment analysis using the g:Profiler online 
database (version e101_eg48_p14_baf17f0) (110). 
Gene Ontology (GO) analysis was performed for the functional annotation of the DEGs. GO 
is an online computational tool providing a systematic and regulated vocabulary to explain 
the current best representation of the normal functions of genes. It consists of different 
ontologies, with each composed of an assembly of terms with well-defined associations 
between the terms. The most common ontologies used to explore the associations of DEGs to 
GO terms in our study were: a) Biological Process (BP) that describe the pathways and 
processes where the DEGs contribute (e.g. transcription and apoptosis), b) Cellular 
Component (CC) describing the location in where the DEGs are active (e.g. lysosome, 
nucleus) and c) Molecular function (MF) describing the molecular activities of each DEG 
(e.g. ligand, transporter).  
For the pathway analysis of the DEGs in our data set, we used Reactome to assess the 
biological pathways put into a broader context. Reactome is a peer-reviewed database, cross-
referenced to different online resources.   
3.7 METHODS STUDY IV 
Saliva sample collection and hormone analysis 
BRCA mutation carriers and wild-type controls collected a daily morning saliva sample   
(~1ml) during one full menstrual cycle. Samples were immediately frozen at ~ -20oC and 
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later transferred into -80oC. Salivary hormone levels were measured using enzyme 
immunoassay kits for progesterone and estradiol, following the manufacturer’s instructions.  
DNAme analysis 
In brief, DNA samples were normalized and bisulfite-modified. The bisulfite-converted DNA 
was then subjected to methylation analysis on Illumina InfiniumMethylation EPIC BeadChip 
(Illumina, CA, USA) as per manufacturer’s standard protocol. The DNAme data were 
background-corrected and normalized (111). Probes were removed if they had < 95% 
coverage across samples and any remaining probes with detection p-value > 0.05 were 
replaced by k-NN imputation, with k=5. The same quality control and normalization 
procedure was followed for 257 breast cancer invasive carcinoma samples with associated 
clinical data and 38 healthy control breast tissue samples with matched gene-expression data 
from a publicly available data bank (The Cancer Genome Atlas) repository 
(https://www.cancer.gov/about-nci/organization/ccg/research/structural-genomics/tcga). 
Bisulfite-sequenced DNAme data for purified breast epithelial cell subtypes were 
downloaded from the European Genome-Phenome Archive (EGA) and reads were aligned 
and counted using Bismark (112) with default settings. Only reads mapping to CpGs 
represented on the Illumina EPIC array were retained and which had a total number of 
mapped reads (methylated+unmethylated) of at least 20. 
Gene expression analysis 
Gene-expression data from 38 healthy control breast tissue samples with matched DNAme 
data available were downloaded from the TCGA repository (The Cancer Genome Atlas, 
https://www.cancer.gov/about-nci/organization/ccg/research/structural-genomics/tcga) and 
were then quantile-normalized using the preprocessCore package in R. 
RNA extraction, cDNA synthesis, and RNA sequencing and analysis 
RNA extraction from paired mifepristone treated samples was conducted and cDNA and 
DNA library preparations were performed as in Study III. Post-quality control reads were 
mapped to the reference genome hg38 using STAR aligner with default settings, further 
filtered and quantified to coding transcripts/genes using hg38 assembly and Ensemble 
transcripts release 91. Gene counts were obtained after filtering for regions fully or partially 
spanned within exon regions.  
Transcriptome data for purified breast epithelial cell subtypes 
Transcriptome data for purified breast epithelial cell subtypes as for the DNAme data were 
downloaded from the European Genome-Phenome Archive (EGA). Transcriptome data for 
purified fat cell samples were downloaded from the ENCODE (Encyclopedia of DNA 
Elements) repository (https://www.encodeproject.org). Read-counts were obtained from the 
archived bam (binary alignment map) files for the RNA-seq libraries (as downloaded from 
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the online repositories) using Samtools featureCounts. TPM (transcripts per million)-
normalized counts were then used for all downstream analyses. 
Real-time PCR 
cDNA was used in triplicates in real-time polymerase chain reaction (RT-PCR) with 
TaqMan® fast advanced master mix and TaqMan® gene expression probe/primer for RANKL 
(Cat no. Hs00243522_m1) and analyzed using StepONE RT-PCR (Applied Biosystems, 
USA). Ribosomal RNA 18s was used as a housekeeping gene to normalize the gene 
expression of RANKL and the relative expression fold change were calculated for the above 
paired treatment groups using the standard formula 2-∆∆CT. 
TP53 mutational analysis by Duplex Sequencing 
TP53 mutations were analyzed using ultra-accurate Duplex Sequencing technique (113) in 3 
non-responders and 5 responders (according to the WID-Breast29 index) using DNA 
extracted from normal breast tissue collected before and after mifepristone treatment. Duplex 
Sequencing kits were used according to the manufacturer’s instructions (TwinStrand 
Biosciences, Seattle, WA, USA). TP53 coding regions were captured by hybridization with 
120 bp biotinylated probes. Two successive rounds of captures were performed to ensure 
sufficient target enrichment (114). Indexed libraries were pooled and sequenced in an 
Illumina MiSeq using v2 300 cycle kits. Data analysis was performed using the standard 
Duplex Sequencing pipeline (113) with updated modifications (https://github.com/Kennedy-
Lab-UW/Duplex-Seq-Pipeline). 
For each sample, we sequenced an average of 5.2M duplex nucleotides in coding TP53 exons 
and calculated TP53 mutation frequency as the number of identified mutant positions/total 
number of nucleotides sequenced in the coding region; TP53 mutation burden as overall 
number of mutant alleles (sum of mutant alleles in all positions) divided by the total number 
of nucleotides sequenced in the coding region. Intronic mutations, except for splice sites, and 
single nucleotide polymorphisms (SNPs) were excluded from mutation analysis. TP53 
hotspot mutations were defined as the top 1% most frequent mutations in breast cancer 
according to the COSMIC database.  
3.8 STATISTICAL ANALYSIS 
3.8.1 Study I 
The current treatment regimen of mifepristone was also used in our previous study where it 
induced amenorrhea in 86% of women after a treatment period of two months (20). Further, 
62% of women reported unscheduled bleeding the initial months after the LNG-IUS 52 mg 
placement (40). To reach 80% power applying a two-tailed test, we had to include 19 women 
in each treatment arm, assuming a reduction of the bleeding/spotting rate from 62% to 21% 
(i.e. reduced to one third). A total of 29 women in each group ought to be recruited, to allow 
for possible drop outs. Descriptive statistics of the study participants are presented with 
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median and range and Mann-Whitney U test was used for comparison between the groups. 
Mann-Whitney U test is a non-parametric test that can be used when variables are not 
normally distributed. A p-value of <0.05 was considered statistically significant. Statistical 
analysis was conducted using the statistical software R version 3.4.3.  
3.8.2 Study II 
No power calculation was conducted for this secondary outcome of the RCT (Study I) and no 
similar investigations have been conducted previously. Descriptive statistics are presented 
with median and range. The Mann-Whitney U test was used for comparison between the 
groups. A p-value of <0.05 was considered statistically significant and data were analyzed 
using SPSS version 25 software (IBM).  
3.8.3 Study III 
No power calculation was conducted for this secondary outcome of the RCT (Study I). The 
filtered gene list was tested for differential gene expression by DeSeq2 between the control 
and treated samples. The DEGs where the fold change was up or downregulated by 2 and 
false discovery rate (FDR) <0.05, were considered statistically significant and were used for 
the downstream analysis using g:Profiler. The Benjamini-Hochberg FDR multiple testing 
correction was used in g:Profiler, with a significance threshold of 0.05 for the functional 
annotation and enrichment pathway analysis of the DEGs (110). FDR (adjusted p-value) is a 
statistical approach commonly used in multiple hypothesis testing, such as high-throughput 
experiments, to correct for multiple comparisons. FDR adjusts the statistical confidence based 
on the number of tests performed.   
3.8.4 Study IV 
The composition of each tissue sample in terms of proportions of epithelial, fibroblast, 
immune and fat cells, based on the DNAme profile of each sample was analyzed using a 
well-validated algorithm (111). The breast epithelial cell subtype inference method for 
DNAme data is available as an R package from:                                                                                                 
https://github.com/tombartlett/BreastEpithelialSubtypes. The composition of cells in each 
tissue sample was analyzed using transcriptome data applying a thoroughly tested algorithm 
(115).  
Non-paired sample t-test was used to analyze DNAme microarray data (with n>10) to 
compare healthy tissue with the tumor, to compare the salivary hormonal levels E2 and P and 
to compare the WID-Breast29 test between the BRCA mutation carriers and control groups. 
Paired t-test was used to compare breast cancer biopsies with the surrounding normal tissue 
obtained from the same women. The significance of the WID-Breast29 index was assessed 
by z-tests on the Wald statistics after fitting a multivariate Cox proportional hazards model. 
Correlation of RANKL expression in luminal progenitor cell fraction was calculated with 




4 RESULTS AND DISCUSSION 
4.1 STUDY I 
4.1.1 Results 
During the study period, 68 women were assessed for eligibility. Of those, 10 were excluded 
prior to randomization due to: ovarian cyst (n=1), positive pregnancy test (n=1), declined 
participation (n=1), cervical dysplasia (n=4), long menstrual cycle (n=3). Consequently, 58 
women were randomized, 29 to mifepristone and 29 to placebo. In the mifepristone arm, 26 
women completed the pretreatment period since three withdrew their consent. In the placebo 
arm, 23 women completed the pretreatment period since 3 withdrew their consent and 3 got 
pregnant. Twenty-three women in each group returned for the LNG-IUS insertion: in the 
mifepristone arm 3 did not receive the device due to failed insertion in 2 and 1 declined 
insertion. All women in the placebo arm received the device. Finally, 4 participants were 
excluded from the bleeding data analysis in the mifepristone group due to; missing bleeding 
data (n=2), chlamydia infection (n=1) and a partial LNG-IUS expulsion (n=1). In the placebo 
group, 4 women were excluded due to missing bleeding data. This resulted in a per protocol 
population of 19 women per treatment arm contributing to the final analysis.  The flow chart 
in the published article also provide the details of the women excluded from the trial.  
During the first 2 months of the pretreatment period, a highly significant difference in mean 
B/S% was reported between the comparator and mifepristone group (p<0.001) with 
mifepristone treated women reporting fewer B/S days. Following the first month after 
insertion of the LNG-IUS 52, women in the mifepristone group still reported lower B/S% but 
with a difference that did not reach statistical significance (p=0.077). A higher proportion of 
women in the mifepristone group reported less moderate or heavy intensity bleeding the first 
month after insertion of the intrauterine device in relation to the comparator group with a 
difference that did not reach statistical significance (p=0.36). A reverse difference was seen at 
3 months post the LNG-IUS insertion, with more days with normal or heavy bleeding in the 
mifepristone arm compared with the comparator group (p=0.044). During the remaining 
observational period (up to 6 months’ post insertion) the B/S rates where low with no 
statistical differences between the groups. Furthermore, there was no difference between the 
groups in in the proportion of women with LNG-IUS removal. No serious adverse events 
were reported during the study period except from the pregnancies that occurred in the 
comparator arm presumably due to lack of adherence to the contraceptive method used.  The 
side effects where mild with no differences between the study arms.  
4.1.2 Discussion 
Our study is the first to explore whether pretreatment with a PRM resulting in amenorrhea, 
could also prevent unscheduled bleeding in new users of a progestin only method (LNG-IUS 
52 mg) in regular cycling women. Women treated with mifepristone reported a significant 
reduction in menstrual bleeding during the two pretreatment months compared to the 
comparator group. Following the pretreatment period, the mifepristone group experienced a 
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reduced but statistically not significant difference in B/S the first month after the LNG-IUS 
placement. The following months, bleeding patterns were similar in the two study arms. 
Furthermore, even though the mifepristone group reported lower rates of normal and heavy 
bleeding the first month after the LNG-IUS placement the difference was non-significant 
with an inverse effect, this time significant, three months after insertion of the device.  
The mifepristone treated women reported 79% of amenorrhea at the end of the pretreatment 
period. This is in line with other studies reporting a high fraction of amenorrhea during 
continuous treatment with PRMs. Studies conducted in women with uterine fibroids and 
heavy menstrual bleeding have shown induction of amenorrhea in 80-90% of continuously 
PRM treated women (69, 116). In a study conducted in our group using the same 
mifepristone treatment regimen as in this study, 86% of women with fibroids reported 
amenorrhea after two months of treatment and close to 100% after three months respectively 
(20). The factors contributing to cessation of bleeding during continuous PRM treatment are 
currently still not well elucidated. Various effects are suggested to contribute, such as 
inhibition of ovulation, compound specific vascular effects and thickening of the arterial wall, 
altered expression of metalloproteinases and endometrial leucocytes as well as altered 
regulation of the ER and PR signaling (116). Treatment duration is also a contributing factor. 
It could also be postulated that the measured treatment effect could be particularly evident in 
women with uterine fibroids and heavy menstrual bleeding compared to normal cycling 
women.  
A literature review revealed a total of ten studies using a PRM to improve bleeding patterns 
in women using a progestin for contraceptive purposes (Table 5) and one study assessing the 
effect of a PRM on bleeding disturbances in women with an LNG-IUS placed due to 
menorrhagia. These studies could further be categorized into PRMs given as prophylaxis or 
as therapy. In the studies exploring the potential prophylactic effect of PRMs, all new 
progestin-only users with regular menstrual cycles were included to prevent unscheduled 
bleeding. The first study by Gemzell-Danielsson et al., included women starting with a 
progestin-only pill, (Cerazette® 75 µg desogestrel daily) in combination with an 
investigational PRM, Org 31710, 150 mg (Organon, Oss, The Netherlands), once every 28 
days for four to seven cycles. A more regular (cyclic) bleeding pattern was observed with 
addition of the PRM compared to placebo (24). Another study, by Jain et al., showed a 
significant decrease in the percentage of days with breakthrough bleeding in new starters of 
the injectable progestin depo-medroxyprogesterone acetate when combined with mifepristone 
50 mg every 2 weeks for 6 months compared to placebo (117). The third study by Massai et 
al., included new users of a subdermal progestin, levonorgestrel releasing implant 
(Norplant®) and mifepristone 100 mg/day administered for 2 consecutive days every 30 days, 
or placebo. They reported the same frequency of bleeding episodes but a total number of 35% 
lower bleeding days compared to the placebo group (118). Another placebo controlled study 
by Warner et al., compared the effect of 150 mg UPA, administered over three consecutive 
days starting on days 21, 49 and 77 after insertion of the LNG-IUS. This regimen showed an 
initial reduction in bleeding/spotting % yet subsequently actually increased compared with 
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that for placebo treated controls (119). During the design of our study we hypothesized that 
pretreatment with endometrial suppression and amenorrhea and subsequent LNG-IUS 
insertion could counteract the increased B/S observed with PRM withdrawal. This effect 
could not be proven, since the mifepristone treated group in our study reported a non-
significant lower occurrence of normal and heavy menstrual bleeding the first month after the 
LNG-IUS insertion compared to the comparator group, while a reverse difference was 
reported at 3 months. Nevertheless, whether adjusted treatment protocols and treatment 
continuing some months after the LNG-IUS insertion could display more favorable results, 
remains to be shown. It could be speculated that maintenance of the suppressed endometrium 
by a PRM until the LNG effect on the endometrium was in place may result in a continuously 
suppressed endometrium and less bleeding, even if ovulation resumes.  
Table 5. Trials using PRMs as prophylaxis or therapy for unscheduled bleeding in progestin-only users. 
  PRM and regimen Progestin Type of study  
Prophylaxis Gemzell-Danielsson 
et al 2002 
Org 31710, 150 mg every 28 days, 
starting on day 1 for  





 Jain et al 2003 mifepristone 50 mg every 2 weeks 
for 6 months starting 2 weeks 
after DPMA injection 
DMPA 150 mg RCT 
 Massai et al 2004  mifepristone 100 mg/day for 2 
consecutive days, on days 30, 60, 







 Warner et al 2009 UPA 150 mg in divided doses (50 
mg/day) given over three 
consecutive days on days 21, 49 






 Papaikonomou et al 
2018 
mifepristone 50 mg every other 
day for two months before LNG-
IUS insertion 
LNG-IUS 52 mg 
(Mirena®) 
RCT 
Therapy Cheng et al 2000 mifepristone 25 mg, two tablets 






 Glasier et al 2002 mifepristone 200 mg as a single 







 Weisberg et al 2006 
pilot study and 
larger follow-up 
trial 2009 
mifepristone 50 mg for one day, 
followed by  
EE 20 µg/day for four days, or 











PRM=progesterone modulator, DMPA=depo-medroxyprogesterone acetate, UPA=ulipristal acetate, LNG-IUS= 




In contrast to the above described studies using PRMs as prophylaxis as in our study, three 
trials used PRMs to improve progestin-only contraceptive bleeding patterns in women 
already experiencing bleeding disturbances thus using PRMs as therapy (23, 120-123). While 
all studies reported a favorable bleeding pattern with the PRM treatment in comparison to 
placebo, none of these studies found an improvement that reached statistical significance.  
Finally, in an open-labelled, non-randomized comparative study, women with heavy 
menstrual bleeding and an LNG-IUS received 100 mg mifepristone every 30 days for 3 
months after placement of the device (not included in Table 5 since the indication for the 
LNG-IUS was heavy menstrual bleeding). Their results showed a significant reduction in 
frequency and duration of intermenstrual spotting compared to the control group which was 
composed after a review of medical records of women who had an LNG-IUS placed (124).  
A recent systematic review was conducted to assess the medical treatment options for 
amelioration of bleeding irregularities in women with LNG-IUS 52 mg (45). Besides the 
studies of Warner et al. (119), Fava et al. (123) and our trial (Study I) as presented in Table 5, 
three more RCTs were identified in women receiving LNG-IUS for contraceptive purposes. 
In one of the trials, new users of LNG-IUS were treated with the SERM tamoxifen or 
placebo, with no statistically significant differences between the groups. The rationale was 
that this SERM could improve bleeding patterns by antagonism of ERβ and consequent 
downregulation of endometrial angiogenesis (125). The second study also included new users 
of the LNG-IUS and women were treated with either an NSAID, an estradiol patch or 
placebo. The group reported a reduction in bleeding and spotting days in the NSAID 
treatment arm while an inverse effect was shown in the estradiol treatment group, compared 
to placebo (126). The third study failed to show a statistical significant difference in bleeding 
irregularities in LNG-IUS users treated with two different antifibrinolytic agents (tranexamic 
acid or mefenamic acid) or placebo (127). The comparison of various studies conducted to 
assess the effects of different agents on bleeding patterns of progestin only users is very 
challenging. Even if most trials use bleeding and/or spotting days as a primary outcome, 
almost all use different definitions for those bleeding irregularities as well as different time 
periods for evaluation, different progestins, interventional agents and treatment regimens.   
Since progestins are PR agonists, there have been concerns regarding the plausible 
pharmacokinetic interactions with any PRMs given because of their antagonistic actions on 
the PR. As previously discussed, continuous administration of sufficient doses of PRMs hold 
the potential to be utilized for contraceptive purposes due to their ability to suppress ovarian 
follicular development. The same contraceptive mechanism of action is adopted by various 
progestin-only preparations including pills, injectables and implants. As a result, even if 
PRMs and progestins exhibits antagonistic or agonistic effects on the PR respectively, in 
sufficient doses they exert the same effect, namely follicular suppression. In the above-
mentioned study by Gemzell-Danielsson et al., a cyclic bleeding pattern was observed in 
women treated with desogestrel 75 µg daily and the PRM Org 31710 once a month compared 
to the women who received desogestrel and placebo (24). This effect on the bleeding pattern 
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could be due to a direct effect on the endometrium and/or a result of the increased rate of 
ovulation observed in the PRM treated group. Nevertheless, no pregnancies occurred in that 
study, nor in the study by Cheng et al., where 300 cycles in women with a levonorgestrel 
subdermal implant and mifepristone were included (23). Furthermore, even with a single dose 
PRM administered directly after ovulation, secretory endometrial changes are avoided which 
could be sufficient to prevent implantation (128). Another study explored whether start with 
desogestrel 75µg immediately following the day after UPA intake for EC could jeopardize 
the effect of the latter. The authors reported a reduced ability of UPA to delay ovulation and 
concluded that this treatment regimen could potentially decrease UPAs efficacy as an EC.  
However, they also concluded that the action of desogestrel was not affected by UPA intake 
(129). In addition, UPA could not affect ovarian quiescence induced by a COC (EE+LNG) 
compared to placebo (130). In summary, the theoretical risk that PRMs may reduce efficacy 
of hormonal contraception have not been demonstrated to date. Properly powered trials 
assessing actual pregnancy incidence with a progestin/PRM combination regimen are needed. 
Even then, given the differences in various progestins and PRMs in progesterone receptor 
affinity and effect depending on which phase of the cycle they are administered, any 
extrapolation to other PRMs or progestins than those assessed should only be concerned 
tentative. The main contraceptive mechanism of the LNG-IUS used in our study is thickening 
of the cervical mucus and not primarily blockage of follicular development.  
In an attempt to reduce the time to LNG-IUS placement, we decided the pretreatment period 
to last 2 months and the women were carefully instructed to use barrier methods for 
contraception. Despite these efforts, 3 women, all in the placebo group, had unintended 
pregnancies. This underlines the major drawback of any pretreatment regimens that do not 
hold contraceptive properties. Even though mifepristone and other PRMs are not licensed for 
contraceptive use, their potential as contraceptive agents have previously been discussed in 
this thesis and even a much lower dose than the one we used, namely 25-50 mg once a week, 
demonstrated high contraceptive effectiveness (59). 
Whether a different treatment regimen, prolonged pretreatment duration or treatment 
stretching over a longer period after LNG-IUS insertion would exhibit a significant 
amelioration of the bleeding disturbances and ultimately lead to higher continuation rates, 
remains to be investigated. Obviously, only a subset of women would actually suffer from 
unscheduled bleeding after LNG-IUS placement and thus could benefit from the use of 
prophylactic treatment with PRMs, such as in our study design. Finding a way to overcome 
this major problem - from a compliance point of view, would be beneficial for a large 
proportion of LNG-IUS as well as other progestin-only contraception users.  
4.2 STUDY II 
4.2.1 Results 
Following randomization in study I, 29 women were assigned to the mifepristone and 29 to 
the comparator arm, respectively. Endometrial samples at baseline were successfully obtained 
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from all study participants in the mifepristone group (29) while retrieval failed in 4 women in 
the comparator group due to narrow internal cervical os, resulting in 25 retrieved biopsies. 
The second biopsy, retrieved 3 months after the LNG-IUS 52 mg treatment with the device in 
situ, was possible in 20 women and 17 women from mifepristone and comparator arm 
respectively. For the histological analysis, one woman from the mifepristone group was 
excluded because of a chlamydia infection and one biopsy was lost in transition to the lab 
after retrieval from a woman in the comparator group. Due to an unfortunate loss of samples 
during the move of our research laboratory, 9 paired biopsies in the mifepristone and 8 in the 
comparator arm respectively, contributed to the final histological analysis. The flow chart in 
the published article also provides the details of women excluded from this study. 
Demographic and reproductive characteristics between study participants in the two study 
arms were similar. 
All endometrial biopsies at baseline were diagnosed as benign, with no signs of hyperplasia 
or atypia. Further, all but one were assessed as physiological, with the majority classified to 
be in secretory phase. The biopsy in the comparator group that was classified as non-
physiological, was overall secretory with occasional dilated glands with subtle architectural 
alterations and compact stroma. No biopsies in either study arm revealed any presence of 
PAEC at baseline.  
The second biopsies with the LNG-IUS in situ were all diagnosed as benign with no presence 
of PAEC. The classification of all biopsies was assessed as non-physiological due to the 
progestin effects of the LNG-IUS. In addition, gland, epithelium and stroma were described 
and vessel evaluation was conducted. The findings are summarized in Table 6. 
Table 6. Summary of the histological classification of endometrial follow-up biopsies collected after the 2-
month pretreatment period with mifepristone or the comparator followed by 3 months of LNG-IUS in situ. 
  Mifepristone  Comparator 
Primary diagnosis: benign  9/9 8/8 
Non-physiological due to progestin effect 9/9 8/8 










Occasional 2/8  
Frequent 1/8 



























The objective of this study was to assess the endometrial morphology and presence of PAEC 
in women treated with a continuous low dose mifepristone preceded by insertion of the LNG-
IUS 52 mg with no endometrial shedding prior to placement of the device. The endometrial 
biopsies at baseline, prior to commencement of mifepristone, were all benign. The follow-up 
biopsies retrieved 3 months after placement of the LNG-IUS revealed progestin effects upon 
histological assessment and no presence of PAEC in either treatment group. The glandular 
architecture in the specimens that could be evaluated upon this feature, was normal in both 
groups. There were one and two biopsies with occasional gland dilation in mifepristone and 
comparator group respectively. In addition, one biopsy in the comparator group displayed 
frequent occurrence of gland dilation. These features were judged as progestin effects and not 
considered a sign of PAEC since the other common and most prominent histologic features of 
PAEC, such as compact non-decidualized stroma, irregular gland architecture and abnormal 
secretion were absent.   
In order not to interfere with the primary outcome of our study (bleeding patterns after the 
LNG-IUS placement), no biopsy was retrieved following the pre-treatment period with 
mifepristone. Consequently, the rate of PAEC developed after mifepristone treatment in our 
cohort is unknown. Studies conducted before the establishment of PAEC as a histological 
entity in 2008, describe morphological features associated with PAEC but often designated as 
glandular hyperplasia. Today, it is widely accepted among pathologists that upon lack of 
information regarding continuous treatment with PRMs, the alterations may be confused with 
endometrial hyperplasia associated with unopposed estrogen effect (74).  Hence, comparison 
with these early studies prior to PAEC definition is unfortunately problematic and uncertain. 
In investigations conducted after establishment of the PAEC criteria, the most utilized PRM 
treatment period is three months’ cycles. A trial conducted in our group, assessed the impact 
of the same mifepristone regimen as in our current study on uterine leiomyoma and found 
PAEC present in 54% of the treated women (20). In another trial from 2003, assessing the 
contraceptive potential of mifepristone, the endometrium of participants displayed 
endometrial alterations with cystic dilations but inactivity, in a dose depended manner, 
already after 30 days of treatment and with much lower doses than ours (2 mg versus 5 mg) 
(14). Further, 3 months’ treatment with UPA could display PAEC in 65-74% of the women 
(68, 69, 74). According to these data, we can postulate that PAEC can develop after 2 months 
with the currently used dosage.   
Treatment with PRMs for uterine fibroid volume reduction and associated excess bleeding 
has been explored and gained even more attention after the introduction of UPA (28, 69). 
Cessation of menstrual bleeding has shown to be rapid and confirmed in 90% of patients 
treated with 5 mg UPA daily, and 88-90% in women treated with 2 mg and 5 mg 
mifepristone respectively (19, 69). In our previous study that used the same mifepristone 
regimen as in the current trial, 86% and nearly 100% of women reported amenorrhea after 2 
and 3 months respectively (20). The mode of action resulting in this rapid induction of 
amenorrhea is still uncertain with some suggestions involving effects on vasculature and 
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especially PR expressing perivascular cells (74). Given the well-established antiproliferative 
and protective endometrial effects of progesterone and progestins, the PR antagonistic 
properties of PRMs have raised concerns about if antagonizing the PR could result in 
unopposed estrogen influence with consequent risk for endometrial hyperplasia and cancer 
development. For this reason, the presence of PAEC remained a key issue regarding 
endometrial safety and with the potential of clinical approval of a PRM as continuous 
treatment, this concern had to be further addressed. There are only two studies evaluating the 
role of progestins on the endometrium after a continuous PRM treatment regimen on PAEC 
development. The first study was conducted in women with fibroids and assessed whether 
presence of PAEC could be reduced by the progestin noretisterone acetate when used for 10 
consequent days after a 3-month treatment course of UPA (72). The second study explored 
the potential of a vaginal ring containing UPA as novel estrogen-free method of contraception 
and utilized a single dose of levonorgestrel to reduce endometrial thickening (PAEC) and 
subsequent heavy bleeding (60). Neither study could, with the progestin regimen, type and 
dose used, display any significant reduction in presence of PAEC despite the fact that 
shedding of the endometrium was reported to be more effective after treatment with a 
progestin. Some limitations should be considered. The endometrial samples were retrieved 
approximately 3 months after cessation of PRM treatment and therefore, related changes 
might have been missed.  In contrast to these studies, no endometrial shedding was part of the 
protocol in our trial, after continuous treatment with mifepristone and before placement of the 
LNG-IUS.   
Taken together, all PRMs studied until today, in continuous regimens for various indications, 
seem to be associated with the development of PAEC. It has been suggested that the variety 
of these endometrial features might differ by agent and dose over time (75). However, in a 
small study (n=9) exploring the endometrial effect of UPA in women with fibroids, the 
degree of PAECs was not correlated to the duration of treatment (131). Another study could 
not demonstrate differences regarding development of PAECs with two different doses of 
UPA (5 mg vs 10 mg) indicating, in this particular study, an absence of a dose-dependent 
effect (74). However, the vast majority of the literature reports a dose- and duration-
dependent effect.  
Our lack of knowledge regarding the specific affinities for various PRMs and their interaction 
with the different PR isoforms in human and consequently the molecular alterations 
underpinning PAEC development currently makes it difficult to compare the plausible 
differences on the molecular level between these compounds. Further, the rate of regression 
of PAEC on cessation of treatment also seem to be variable (72) and not all women develop 
PAEC, which accordingly implicates individual variations. Even though PAEC following 
treatment with PRMs are now considered benign due to lack of atypia and mitotic features, 
the molecular alterations underpinning their development are not yet delineated. Adopting 
therefore a more prudent approach, we need a greater understanding of the molecular and 
cellular mechanisms responsible for these histological features and also distinguishing the 
different compounds and assess them separately. Thus, more studies are required to better 
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define PAEC development, long-term effects possibly even without cessation of treatment as 
well as possible treatments to counteract their appearance in order to expand the use of PRMs 
and hence allow major improvements in women’s health. It can be concluded that PAEC can 
be ceased by shedding of the endometrium. Our study indicates that placement of a LNG-IUS 
directly after continuous treatment with mifepristone, could be a safe alternative regarding the 
endometrium. Whether PAEC could resolve without need of endometrial shedding or even be 
reversed by the influence of the LNG-IUS, has to be investigated in larger trials.  
4.3 STUDY III 
4.3.1 Results 
Following randomization, 29 women were allocated to mifepristone or the comparator 
respectively. Only women from the mifepristone arm were included in this sub-study. At 
baseline, 28 core needle biopsies were retrieved due to one woman withdrawing her consent. 
Following the 2 months’ mifepristone treatment, 25 women provided biopsies since 2 
withdrew their consent and one dropped out. Thereafter, one participant was excluded since 
she did not take the study medication according to the protocol. Finally, 16 randomly chosen 
paired breast samples contributed to the final analysis.  
To study the molecular alterations in the breast following mifepristone treatment, we assessed 
the changes on mRNA expression levels at baseline compared to after treatment. After RNA 
sequencing of whole breast tissue, we found 27 differentially regulated genes (DEGs) of 
which 19 were upregulated and 8 downregulated respectively. The results of the top enriched 
Gene Ontology terms in each of the three categories (BP, biological process; CC, cellular 
component; MF, molecular function) for upregulated DEGs were ‘extracellular matrix 
organization’, ‘collagen-containing extracellular matrix’ and ‘platelet-derived growth factor 
binding’. The functional annotation for the downregulated DEGs revealed one significantly 
enriched term, in category MF, namely ‘active borate transmembrane transporter activity’ 
with the involvement of solely one gene.   
The Reactome pathway analysis showed that the upregulated DEGs were significantly 
enriched in 54 biological processes, of which the top 10 were mainly associated with 
extracellular matrix organization. The downregulated DEGs revealed only two genes 
involved separately in 6 pathways.  
4.3.2 Discussion 
The objective of this study was to explore the in vivo molecular response of the mammary 
gland to progesterone antagonism in healthy women. We used next-generation whole 
transcriptome sequencing (RNA-seq) for the paired samples at baseline and after 2 months’ 
treatment with mifepristone. Subsequent bioinformatics analyses were conducted. The 
upregulated DEGs were mainly enriched in ‘extracellular matrix organization’, ‘collagen-
containing extracellular matrix’ and ‘platelet-derived growth factor binding’ and the 
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significantly altered pathways in biological processes were also mainly related to the 
extracellular matrix (ECM) organization.  
It is widely accepted that the ECM plays an important role in tissue homeostasis. A constant 
remodulation is achieved through a complex but far from well elucidated crosstalk between 
ECM components and adjacent cells during development and the monthly cyclical 
proliferation and apoptosis of the breast tissue (132). It is therefore of no surprise that 
aberrant responses in ECM dynamics are proven to be associated with various pathologic 
conditions, tumorigenesis and cancer invasion (133). In our study, most of the DEGs 
involved in the enriched pathways code for pro-collagens. Collagens constitute the major 
structural proteins of the ECM. Evidence points at both collagen content and alignment 
within the ECM playing a role in tumor cell invasion (134). Furthermore, breast density as 
assessed by mammography constitutes an independent risk factor for breast cancer 
development although the underlying mechanisms responsible for this observation are not 
well understood (86, 134). Studies have shown an increase in mammographic density in 
women using hormone replacement therapy (97). It has been further suggested that increased 
collagen production by stromal fibroblasts lead to a firmer ECM resulting in alterations in 
focal adhesions within the tissue, leading to altered signaling pathways and ultimately 
distorted epithelial cell behavior (134). In our material, the enriched pathways reflect an 
increased remodeling of ECM compared to baseline, with both ‘collagen degradation’ as well 
as ‘collagen formation’ emerging as enriched pathways. These findings suggest that ECM 
may play an important role in PR antagonism in breast tissue which is in line with previous 
evidence advocating the ECM as an important regulator of homeostasis, tumorigenesis and 
cancer progression in the mammary gland (132, 133).  
In addition to DEGs encoding for pro-collagenases, other DEGs involved in the enriched 
pathways presented are metalloproteinases which process pro-collagens that will 
subsequently be deposited as collagen fibrils into the ECM. Metalloproteinases are suggested 
to exhibit an important role in the physiological process in the breast but also in 
tumorigenesis, cancer progression and metastasis (132, 135). We found ADAMTS2, a matrix 
metalloproteinase to be involved in the enriched pathways ‘collagen biosynthesis’ and 
‘collagen formation’. Even though members of ADAMTS family have been demonstrated to 
be involved in angiogenesis and cancer, ADAMTS2 seems to inhibit angiogenesis and 
consequently tumor growth (136). Furthermore, no significantly altered expression levels 
could be seen in ADAMTS2 in malignant compared to healthy breast tissue (137).  MMP2 is 
another metalloproteinase involved in the enriched pathways ‘degradation of the extracellular 
matrix’ and ‘collagen degradation’ in our material. Investigated in breast cancer, increased 
levels of MMP2 have shown an inverse correlation to prognosis while other studies suggested 
a dual role depending on the stage of the disease (132, 138). In a study conducted in healthy 
women donors, 15 breast samples were investigated using RNA-seq as in our study (139). 
The stage of the menstrual cycle was retrospectively assessed by serum progesterone levels 
collected by the time of the breast biopsy. One biopsy was collected from each woman and 
therefore the intra- and interindividual variation could not be taken into account. The group 
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reported a higher expression of matrix metalloproteinases MMP3 and ADAMTS9 in the 
luteal phase of the women’s menstrual cycle. Since the luteal phase represents the 
proliferative phase in the breast, these findings may suggest that MMPs and consequently the 
ECM play an important role in breast proliferation. Hence, their counteraction could be 
hypothesized as a breast protective approach. If this could be achieved by PRM treatment, 
remains to be demonstrated in larger in vivo trials. MMP3 is implicated to be involved in 
mammary gland branching morphogenesis in mice (139).  
Due to availability limitations of mammary gland from healthy women, the vast majority of 
human studies are conducted from tissue deriving from breast cancer patients. Even though 
the results may have shed light into different potential models regarding cancer development 
and progression, the complexity and heterogeneity of the tumors are major obstacles in 
interpretation of the results. With advanced technologies, a growing number of potential 
important genes with altered expression are emerging to exhibit dual roles in different stages 
of the disease making interpretation even more complex. In addition, many comparisons are 
made between breast cancer tumors and healthy breast, with the latter however excised from 
the periphery of the breast cancer. This tissue may display benign histopathological features 
but could already express unfavorable molecular alterations due to the tumor proximity. 
There is only one previous study exploring the effect of a PRM on breast tissue in healthy 
women in vivo (27). That trial, conducted in our group, used the same mifepristone regimen 
as we did in the current study but for 3 instead of 2 months and the breast biopsies were 
collected with a fine needle. The expression of the proliferation marker Ki-67 in the epithelial 
cells, assessed by immunocytochemistry was downregulated, indicating a potential protective 
effect of mifepristone in the breast. The current study is the first to explore the molecular 
alterations, and in particular the transcriptomic landscape in heathy breast tissue in vivo, 
following progesterone antagonism. We used paired biopsies in an attempt to reduce the 
interindividual variability of the response. Even though the sample size was quite limited, and 
the samples were not pooled into different cell lineages, given the lack of similar data this 
study still provides us with unique findings with the ECM seemingly playing an important 
role in the potential protective effects of PRMs.  
A study exploring the impact of UPA in normal breast tissue could not exhibit any impact on 
the mitotic index (140). Even though the tissue used derived from healthy women, the study 
was conducted in vitro and in xenografted athymic mice with a treatment duration of 28 days. 
The results should therefore be interpreted with caution. Furthermore, the differences 
between mifepristone and UPA should also be considered in terms of affinity towards the 
other steroid receptors beside the PR. As previously described, mifepristone binds to some 
extent to the AR, as does UPA albeit to an even lesser extent (15). The androgen testosterone, 
has shown suppression of proliferation in human breast cancer cell lines (141). In addition, 
reduced serum androgen levels were found in women after 2 months treatment with COC 
(EE/levonorgestrel) while their breast biopsies showed increased breast proliferation in 
comparison to the baseline and the comparator group with no COC use (142). Furthermore, in 
our previous study where mifepristone showed a significant reduction in the proliferation 
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marker Ki-67 in the breast, there was also a significant elevation of testosterone (27). These 
data may suggest that increased androgen levels may have an inverse effect on breast 
proliferation and that consequently AR antagonism may also play a role.  
Epithelial cells in the breast are thought to derive from a pool of precursor cells, the 
mammary stem cells (MaSCs) which are necessary for the hormonally driven response of the 
mammary gland (97). Following identification of the mammary stem cell, a lot of studies 
have been conducted but despite numerous experimental observations the location of MaSCs 
within the glandular epithelium and their differentiation potential still remains elusive (143). 
As previously discussed, only a minor fraction of epithelial mammary cells in the normal 
breast express PR and MaSCs are reported to lack PR (139). Consequently, paracrine signal 
mediation of progesterone and other PR ligands into adjacent PR- epithelial cells with the 
help of RANKL and the involvement of ECM could be hypothesized to constitute a central 
concept.  
4.4 STUDY IV 
4.4.1 Results 
Estradiol and progesterone were measured from daily saliva samples over the course of one 
menstrual cycle in BRCA1/2 mutation carriers and confirmed non-carriers. Both hormones 
showed significantly higher levels in the BRCA1/2 group compared to the control group.  
High prevalence of DNAme in polycomb-group target genes has been implicated in cancer 
(144) and with increasing age (145). Potential DNAme sites (CpG dinucleotides) within 
polycomb-group target genes have been identified and are suggested to define a tick rate that 
correlates with the estimated number of lifetime accumulated stem cell divisions (mitotic 
age/replicative age) in normal tissues (146). This mitotic clock, named pcgtAge, has further 
been refined in this study to generate a more breast specific epigenetic index. This new index, 
named WID-Breast29 (Women´s risk Index for Breast 29), includes a subset of 37 CpGs in 
29 genes selected from the CpGs in the original pcgtAge panel. The CpGs included, were 
selected based on increased DNAme scores in normal breast tissue from BRCA1/2 women 
compared to confirmed non-carriers. For validation, WID-Breast29 was applied and scored 
higher in breast tissue from the vicinity of TNBC than breast tissue from healthy volunteers. 
Similarly, the index score was higher in tissue from the tumor of TNBC patients compared to 
its adjacent tissue. In addition, the index was higher in ER+ and PR+ breast cancers 
compared to that of the adjacent histologically normal breast tissue.  
Bulk breast biopsy tissue was used for the above-mentioned comparisons. To minimize the 
risk of the differences in replicative age being merely a reflection of differences in cellular 
composition, all tissue samples were assessed again, this time using a well validated 
algorithm (147). This algorithm was applied sequentially, by first estimation of the 
proportions of four main cell-types (epithelial, adipose, stromal and hematopoietic) and then 
further by decomposition of the epithelial compartment into luminal progenitor, mature 
luminal, and basal (myoepithelial) subtypes. Then, a new custom-defined DNAme was 
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assembled with reference profiles for these epithelial subtypes based on previously published 
whole-genome bisulfite-sequencing data (148) by adapting the original algorithm (147) used 
to obtain these profiles for each individual cell-type. With this new classifier, a marked 
increase in the number of luminal progenitor cells was demonstrated in TNBC compared to 
adjacent breast tissue, while the number of mature luminal cells remained unchanged and that 
of basal cells decreased.  
Further, we assessed whether PR antagonism with mifepristone could modulate the DNAme 
index for replicative age and luminal progenitor cell proportion. WID-Breast29 in 
conjunction with the epithelial cell-subtype classifier was applied in breast samples of 15 
BRCA mutation carriers and 20 controls at baseline and after 2-3 months treatment with 
mifepristone (11 BRCA carriers and 9 controls) or the comparator (4 BRCA carriers and 11 
controls). These volunteers originate from Study I and our ongoing BRCA study. The WID-
Breast29 score did not differ in women treated with the comparator, while it was significantly 
lower in women treated with mifepristone. In the mifepristone treated BRCA mutation 
carriers, 7/11 (64%) showed a reduction in WID-Breast29, while in the control group the 
reduction could be detected in all women (9/9). In addition, luminal progenitor cell fraction 
was not affected in the comparator treated women, while mifepristone exhibited a decrease in 
9/9 (100%) of control volunteers and 8/11 (73%) in BRCA mutation carriers. Two of three of 
the BRCA mutation carriers who did not show a decrease in the fraction of luminal 
progenitors showed no decrease in their WID-Brest29 index either.   
The effect of UPA on breast in women judged to have a higher breast cancer risk, was also 
evaluated. The comparison between baseline and after treatment biopsies revealed a 
significant reduction in WID-Breast29 in some women.  
Further, we wanted to assess the impact of mifepristone on TP53 mutation frequency in 
women deemed to respond to mifepristone based on the reduction in WID-Breast29 index. 
T53 mutations could be detected in 7 of 8 samples analyzed. The TP53 mutation frequency 
was found to be unaltered in 3 volunteers who showed an increase in WID-Breast29 index. 
The TP53 mutation frequency showed a significant decrease in 5 volunteers who also had a 
decrease in WID-Breast29 index.   
4.4.2 Discussion 
Elevated estradiol and progesterone levels measured in saliva were demonstrated in 
BRCA1/2 mutation carriers and are in line with previous observations when measured in 
serum (104). These elevations could be implicated in enhanced progesterone signaling and 
consequently mitotic action in the breast of BRCA mutation carriers compared to non-
carriers. Furthermore, higher WID-Breast29 score in BRCA mutation carriers suggests an 
accelerated replicative (mitotic) age of their mammary epithelium as in tissue adjacent to 
cancer. This observation may explain their increased breast cancer susceptibility.  
In our two clinical trials (Study I and the BRCA trial), none of the women in the comparator 
arm showed any alterations in WID-Breast29. The healthy women from Study I, treated with 
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mifepristone, showed all a reduction in WID-Breast29. In BRCA1/2 mutation carriers, 7 out 
of 11 (64%) showed a reduction. This could imply a PR independency adopted in these 
particular women. Further, luminal progenitor cell fraction was not altered after the 
comparator intake, while in the mifepristone group, 100% and 73% of the control and BRCA 
group respectively showed a decrease. PR activation of luminal epithelial cells have been 
shown to drive proliferation of adjacent PR- cells in mice through paracrine mechanisms via 
RANKL (94). In humans, RANKL expression has been demonstrated in breast tissue of 
women with high serum progesterone levels (95). Hence, a protective effect following 
mifepristone could be hypothesized. Upon assessment in women judged to have a high risk 
for breast cancer, UPA, another PRM, could demonstrate similar effects assessed by WID-
Breast29. These results are in contrast to the studies of UPA in breast tissue from healthy 
women assessed in vitro and xenografted in athymic mice (140). This discrepancy may 
reflect the differences between the in vivo and in vitro milieu. Further, the duration of 
treatment was one month in the above-mentioned ex-vivo study and the assessment was based 
on immunohistochemistry. However, the number of participants were few in both studies and 
the results have to be further confirmed.  
The WID-Breast29 index presented in this study is proposed as a DNAme based index 
reflective of the mitotic age in the breast. It seems mainly correlated with the change in 
luminal cell progenitor fraction. Moreover, WID-Brest29 score is highest in breast cancer 
cells, followed by breast tissue from tumor adjacent sites and is lowest in mammary 
epithelium from healthy women.  The number of luminal progenitor cells and the WID-
Breast29 index is reduced following PRM treatment, in BRCA1/2 mutation carriers, non-
carriers and women with a higher risk for breast cancer. These data strengthen the prospects 
of progesterone receptor antagonism as an attractive approach to be further evaluated, in 
particular in BRCA mutation carriers in which the most effective means of cancer prevention 
in still the surgical removal of organs at risk. Monitoring patient responsiveness of risk 
reduction trials could be facilitated using the WID-Breast29 index. 
4.5 METHODOLOGICAL CONSIDERATIONS 
4.5.1 Study I 
Study I, is a randomized double-blind placebo controlled trial and as such provides one of the 
most robust levels of scientific evidence. When well conducted, the randomization 
inclusively blinding process reduces selection and allocation bias and subjects as well as 
investigators expectations, and thus known and unknown confounding variables. Hence, it 
improves internal validity by reducing random as well as systematic errors (bias) and 
consequently improves external validity (generalizability) (149, 150). The per protocol 
analysis and possible bias from women that were lost to follow-up (attrition bias) or 
discontinued for various reasons is a limitation of our study.  
The mifepristone dosage used was 50 mg every other day. The rationale for this treatment 
regimen was that we aimed for the lowest possible dose with proven effect on amenorrhea. 
 
 55 
However, mifepristone tablets below 200 mg are not available in Europe. A high dose-
dependent induction of amenorrhea ranging from 63-100% has been reported during 
mifepristone treatment with low continuous doses, varying between 2-50 mg daily (19, 151). 
In addition, in the previous study conducted in our group, the same treatment regimen as in 
Study I, resulted in 86% of amenorrhea within two months (20). Given the long half-life of 
mifepristone, we assumed that 50 mg every other day would correspond to a daily dose of 
approximately 25 mg. We could at the same time overcome our lack of access to low dose 
tablets by dividing the available 200 mg tablets into 4 parts. According to the available data 
presented above, even a lower continuous dose could induce amenorrhea but at a lower rate.  
The effect of pretreatment with a PRM on bleeding disturbances following progestin 
treatment had never previously been explored and appeared as an attractive approach to 
assess. At the same time, it is well known that commencement of contraception as prompt as 
possible after decision making is beneficial for women by reducing their time at risk for 
undesired pregnancy. With this fact in view, we decided to shorten the pretreatment period to 
2 months. Since amenorrhea following PRM treatment is also dependent on duration of 
treatment, we postulated that an even shorter pretreatment period would be too brief to induce 
amenorrhea in a sufficiently high proportion of women in our cohort. Despite these efforts 
and comprehensive counseling regarding the need of contraceptive use (condoms) throughout 
the pretreatment period and in addition 7 days after the LNG-IU placement, 3 study 
participants got pregnant. All the undesired pregnancies were in the comparator arm. These 
unfortunate events stress the need of any eventual pretreatment regimen to possess 
contraceptive properties.  
We used a quarter of a table TrioBe® every other day as a comparator in our study. 
Investigations regarding possible effects of B vitamins on the menstrual cycle are scarce. One 
study reported a statistical significant difference on bleeding and spotting in women with a 
copper IUD treated with daily vitamin B1 100 mg compared to placebo (152). No 
measurements of micronutrient status were conducted at baseline and therefore, it is not 
known if some women had a B1 deficiency at study start which have been corrected by B1 
vitamin intake and may thereby influenced the study results. B1 is not included in TrioBe®. 
Another study assessed the dietary intake of B2, B6 and B12 on ovarian function of healthy 
premenopausal women. No statistical significant associations could be observed between 
intake of B vitamins and ovarian cycle function (153). In our study, we assumed that the 
effect of TrioBe® on menstrual bleeding patterns, if any, would be negligible with the current 
dose used.    
No liver function evaluation was conducted during our trial. Cases with transient elevations 
of serum liver transaminases have been reported and varied depending on the PRM used, the 
dose and duration of treatment. Our study was conducted prior to the alarm regarding liver 
failure during UPA treatment for uterine fibroids. In hindsight, measurements of 
transaminases during study treatment would obviously be reassuring. Nevertheless, no 
elevation of transaminases was measured during the 3-month treatment with the same PRM 
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and treatment regimen in our previous study (20). Moreover, no participant reported 
symptoms suggestive of liver injury during our trial with the last telephone follow up 12 
months after the LNG-IUS insertion.  
Study participants estimated their vaginal bleeding according to the bleeding scale provided. 
There are several methods to measure menstrual bleeding more precisely such as the alkaline 
hematin and different pictorial assessments. Even if self-assessment is of course objective, it 
is ultimately the one that accounts for satisfaction, acceptability and possible premature 
discontinuation of the LNG-IUS in the general population.  
4.5.2 Study II 
There are several strengths in this trial. The participants were derived from the RCT of Study 
I and the endometrial assessment was conducted by one pathologist who was blinded to the 
treatment. He is also one the most recognized pathologists regarding PAEC.   
Since this was a secondary outcome and in a sense a pilot study and no previous similar 
studies are reported in the literature, no power estimation has been conducted. Further, in an 
attempt not to interfere with the primary outcome of Study I, no endometrial biopsy was 
retrieved after the 2 months treatment with mifepristone and prior to placement of the LNG-
IUS. As previously discussed, due to this reason, we are not aware of the proportion of 
women that actually had developed PAEC by the end of the pretreatment period. Given the 
lack of similar studies though, our results implicate that a larger, properly powered trial, 
would be of great interest to further test the hypothesis that LNG-IUS for contraceptive 
purposes could be adopted without prior endometrial shedding after continuous treatment 
with PRMs. 
4.5.3 Study III 
A significant strength of Study III is the use of human in vivo biopsies from a randomized 
controlled trial. As discussed throughout this thesis, breast biopsies from healthy women are 
valuable since they are extremely scarce.  
The breast biopsies were retrieved under ultrasound guidance. Experienced radiologists are 
able to, by means of sonography, distinguish the various anatomical structures within the 
breast and retrieve targeted biopsies from the most glandular areas within the mammary 
gland (154). One experienced radiologist collected all breast biopsies on our trial, minimizing 
thus the interobserver variability introduced by several investigators. The follow-up biopsies 
were collected from the same area also under ultrasound guidance. The same approach has 
been adopted in other studies previously, in an attempt to minimize variations in localization, 
due to the well-known heterogeneity and regional differences within the breast (27, 80). 
Furthermore, biopsies were collected with a core needle providing us with enough material 
for our downstream analysis. Fine needle aspiration (FNA) biopsies provide exclusively cells 
as material, often with low cellular content (27) instead of tissue, as in core biopsies.  
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Molecular alterations precede morphological and biological modifications of various 
responses. With advanced technologies, attention has been able to shift from functional and 
morphological changes of various diseases, drug responses and developmental stages in 
physiological conditions, to the molecular mechanisms underpinning these changes. NGS 
technology has the last decade revolutionized the field of differential gene expression studies 
since they offer scalability, high-throughput and consequently speed. High-throughput 
sequencing (massive parallel sequencing) allow for measurement of gene expression 
quantification of tens of thousands of genes in one experiment (155). RNA-seq is of 
particular interest since it reflects a snapshot of the entire transcriptional profile instead of a 
predetermined subset of genes as with reverse transcription PCR as well as microarrays. In 
addition, with RNA-seq, it is possible to detect novel transcripts and sequence variations of 
the transcribed regions (156). Consequently, for the above-mentioned reasons and due to the 
scarcity of healthy breast tissue, we considered RNA-seq as the best available option to assess 
our material.  
Despite the advantages of high-throughput technologies, analysis and interpretation of the 
gene lists generated are challenging, and would be practically impossible to assess by manual 
literature search. Therefore, there is today hundreds of databases providing pathway 
enrichment analysis which makes interpretation more feasible and offer useful insights into 
biological mechanisms. We used the free-online database g:Profiler for the functional 
annotation and pathway enrichment analysis. This software is currently one of the most up-
to-date databases (157). GO was used for the functional annotation (attachment of biological 
functions and their relationships to gene sets) of the DEGs in our data set. Further, Reactome 
was used for the pathway enrichment analysis. Reactome is a human pathway database 
manually curated (experimentally validated) and peer-reviewed. Pathway enrichment analysis 
identifies biological pathways that are enriched (over-represented) in the gene list, as 
compared to all genes in the human genome, more than it would be expected by chance 
(157). Given the plethora of databases, there is an ongoing debate regarding which ones are 
more appropriate to use. The answer, if there is one, is complicated. There is a number of 
factors that should be considered upon selection for downstream analysis depending on the 
hypothesis and the experiment. In experiments dealing with human tissue, a database of 
human pathways should be utilized. Furthermore, an updated and curated peer-reviewed 
database is considered better to use, rather than a non-curated one which implies minimal 
standardization and a wide degree of freedom for data documentation. There are also some 
points to be considered in general. First, the pathway boundaries of various databases tend to 
be arbitrary, giving occasionally diverse results. Some scientists argue that different databases 
should be tested upon to decide which interprets the experimental data better. Second, the 
gene lists incorporated are biased towards well-known pathways. In fact, genes with no 
systematic pathway annotation are ignored in pathway enrichment analyses. Results are 
therefore also changing overtime as more data are integrated into the databases. Third, genes 
that are multi-functional may lead to enrichment of many biological pathways. Some of them 
may not be necessarily relevant to the conducted experiment and therefore, some suggest that 
 
58 
those genes should be excluded from the analysis. Fourth, enrichment analysis is more 
effective for pathways where various differentially expressed genes (genes with strong 
biological signals) cluster. As a consequence, pathways controlled by only a small number of 
genes will not be detected as enriched. That doesn’t necessarily mean that these genes are not 
important regulators. Fifth, the statistical analysis incorporated, most commonly FDR (a 
multiple testing correction method) is often more or less conservative than optimal. In any 
case, statistical significance or not, may not always equal to absence or presence of biological 
significance. Nevertheless, it should still be utilized for exploratory analysis and hypothesis 
generation (157). In summary, these quite new methods provide a huge amount of new 
information with tremendous possibilities. The interpretation of the data though, is still 
challenging with potential of improvement. Until further, validation with more conventional 
methods of any given results should be considered.  
The current mifepristone dose and dosage used, has previously shown a reduction of breast 
epithelial cell proliferation in healthy breast after 3 months of treatment (27). In our study, the 
treatment period was 2 months, in attempt to reduce the time to the LNG-IUS insertion as 
described for Study I. Trials on COCs have demonstrated breast epithelial cell proliferation 
after two months of treatment (142) and breast biopsies in healthy women with no hormonal 
treatment could show an increase in proliferation in mid-luteal phase compared to early 
follicular phase within one menstrual cycle (80). Based on these observations, we assumed 
that a 2 month treatment with mifepristone would be enough to demonstrate changes in the 
mammary gland.  
Even though breast biopsies in our study were retrieved under ultrasound guidance in an 
attempt to include as much glandular tissue as possible, the specimen retrieved for 
downstream analysis should be considered bulk (mixed) tissue. Bulk tissue in RNA-seq 
experiments is a widely-adopted method to study transcriptomic alterations in different 
conditions. However, given bulk tissue heterogeneity, the specific cell types cannot be 
discerned and spatial information is therefore not preserved (158). Hence, our results may be 
biased due overrepresentation of a certain cell type in the biopsy and we cannot rule out that 
additional significant results are diluted and therefore not represented in the list of DEGs in 
our study. Nevertheless, since transcriptomic signature following PR antagonism has never 
previously been explored, investigation of the whole tissue may provide a more 
comprehensive approach and reveal specific points of penetration for future research.   
4.5.4 Study IV 
Changes in the epigenetic landscape is commonly assessed by evaluation of the total amount 
of methylation present in the DNA which subsequently affect gene expression. In this study, 
a breast specific epigenetic index was developed and used as a surrogate marker in 3 different 
patient cohorts to further assess the impact of PRMs in breast tissue. This was a collaboration 
with well-known experts in the field and established algorithms were used. Another strength 
is the in vivo biopsies included. Having BRCA mutation carriers participating in this study is 
also a strength since these patients have a higher risk for breast cancer in young ages. They 
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may represent “an in vivo model” with accelerated processes leading to cancer development. 
It is therefore interesting to evaluate any impact of treatment to gain deeper insight in steroid-
related alterations in the mammary gland. There are several limitations such as the small 
cohorts included. Further, the BRCA mutation status is not known in the women included 
from Study I and the duration of mifepristone treatment differs. As previously discussed, the 
treatment duration in Study I and the BRCA trial was 2 and 3 months respectively. This 
difference could have an impact treatment response, even if it was not reflected in the results 
of this particular study. The algorithms used as surrogate markers for risk of breast cancer 























5 SAFETY OF LONG-TERM TREATMENT WITH 
PROGESTERONE RECEPTOR MODULATORS 
Side effects following continuous low dose PRMs are in general mild and transient with the 
most common reported to be headache and hot flushes (73). In patients with Cushing’s 
syndrome that receive ≥300 mg mifepristone daily, the most common adverse effects 
reported are nausea, fatigue, headache and hypokalemia (159).  
As previously described, mifepristone, as well as UPA, also bind to the GR in a dose 
dependent manner. Single doses of mifepristone exceeding 200 mg are capable of activating 
the hypothalamus-pituitary-adrenal (HPA) axis, reflected by rises in serum concentrations of 
cortisol, adrenocorticotropic hormone (ACTH) and dehydroepiandrosterone sulfate 
(DHEAS). When mifepristone is given in lower continuous doses, 50 mg daily is reported to 
exhibit a raise in serum concentration of cortisol and DHEAS at 12 weeks of treatment (28). 
Mifepristone at a dose of 25 mg every other day (27) and daily doses of 10 mg (58) did not 
affect cortisol levels. It should though be noted that another trial could not detect any 
significant changes in cortisol levels with 50 mg daily compared to placebo (22) and no 
clinical signs of adrenal failure have been reported with low treatment doses despite the 
alterations of serum cortisol levels (160). However, the studies are rather few with limited 
number of participants.   
PRMs have been proven not to induce hypoestrogenism despite their ability to block 
follicular growth and induce amenorrhea (57, 161). Bone mineral density remained unaltered 
in a small study (n=9) in women treated with mifepristone 50 mg daily for 6 months (22).  
Subjects with elevation of liver enzymes have been reported in trials using continuous doses 
of different PRMs for various indications. The assessment of this side effect and whether it is 
a class effect and to which extend, is tremendously impeded by a number of factors. The 
affinity, selectivity and pharmacokinetic as well as pharmacodynamic differences between 
different compounds. Further, the variations in dose, dosage and duration of treatment 
adopted in various trials. While most studies report mild and transient elevation of liver 
enzymes even without cessation of PRM treatment, phase 3 trials have been suspended due to 
liver toxicity in women treated with the PRM telapristone acetate 50 mg daily (1, 116). 
Clinical trials have thereafter been employed using lower doses of telapristone acetate and 
alternative routes of administration (Table 1, section 1.2) (1). The development of another 
PRM, onapristone, was also stopped due to hepatotoxicity. Recently, an extended-release oral 
formulation of onapristone has been developed and is currently tested in a phase 2 trial in 
PR+ gynecological cancers (Table 1, section 1.2) (162). UPA was authorized in the European 
Union in 2012 for treatment of moderate to severe symptoms of uterine fibroids. In 2018, five 
cases of lever injury were reported in women treated with UPA, of which four required liver 
transplantation. The European Medicines Agency decided upon repeated measurements of 
liver transaminases to minimize the risks, with the recommendation of cessation of treatment 
when transaminases exceeded three times the upper normal limit. Despite these measures, 
one more liver transplantation was eventually required, which led to the current 
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recommendations of UPA being prescribed for treatment of uterine fibroids only when 
surgery is not possible. In summary, five cases of liver transplantations due to serious liver 
injury occurred in over 900.000 women treated with UPA (163). Single-dose treatment with 
UPA for EC is not affected by the restrictions described above.  
Continuous doses of PRM are also associated with PAEC, as reviewed and discussed 

























6 ETHICAL PERMITS AND CONSIDERATIONS 
The study protocols were designed according to the recommendations in the CONSORT 
statement.  They were approved by the ethical committee at Karolinska Institutet, Stockholm 
Sweden. Study I, II, III: Dnr: 2009/144-31/4. ClinicalTrials.gov identifier: NCT01931657. 
Further, approval was obtained from the Swedish Medical Products Agency (EudraCT 
number 2009-009014-40).  
In Study IV, participants from Study I were included as well as BRCA mutation carriers from 
clinical trial with Dnr: 2012/729-31/1, 2014/703-32 and ClinicalTrials.gov identifier: 
NCT01898312. Approval was also obtained from the Swedish Medical Products Agency 
(EudraCT number 2012-003703-35).  For the other participants, ethical permits have been 
obtained from respective regulatory authority.  
All participants gave written informed consent prior to randomization and received oral and 
written information inclusively the lack of contraceptive properties in both the active as well 
as the comparator substance. Participants past medical and reproductive history was reviewed 
and they were carefully examined. They received contact details (telephone number and e-
mail address) to the WHO center for any additional contact if needed, apart from the planned 
return visits. Women with abnormal Pap-smear findings were excluded from the study and 
referred to our gynecological department for further investigations as per clinical routine. The 
LNG-IUS is a well-documented, highly effective LARC. The insertion cause patient 
discomfort which usually resolves rapidly. All women were offered paracetamol prior to the 
insertion. A vaginal ultrasound was conducted before and after placement of the device to 
ensure optimal localization. No uterine perforations occurred. Mifepristone side effects with 
the dose and treatment regimen used are mild and usually transient. To reduce the time to 
LNG-IUS placement, the pretreatment period in the trial was reduced to 2 months. Despite 
these efforts, three pregnancies occurred in the comparator group which emphasizes the need 
for a reliable contraceptive potential in any pretreatment regimen used in clinical practice. 
The participants that got pregnant decided to terminate the pregnancy and were referred to 
our gynecological clinic for further care.   
All biopsies were coded after retrieval to ensure anonymity before transportation to our 
research laboratory. The collection of biopsies are invasive procedures which cause patient 
discomfort. Study participants received a detailed explanation of the study procedures, local 
anesthetics were used for the retrieval of the breast biopsies and all patients were informed 
that they could deny further participation in the study even without stating reason. This would 
by no means affect possible future treatments. Study participants that did not wish for a LNG-
IUS placement or wanted their IUD removed, were offered comprehensive counselling 







• Mifepristone given as pretreatment prior to LNG-IUS insertion resulted in 
amenorrhea. After pretreatment the difference in bleeding and spotting days did no 
longer reach statistical significance and the vaginal bleeding patterns were similar 
within the two study groups.  
 
• Following placement of a LNG-IUS 52 mg directly after continuous treatment with 
mifepristone, with no prior endometrial shedding, no PAEC was observed. Larger 
appropriately powered trials are needed to confirm this reassuring finding.   
 
• Transcriptome analysis of human breast tissue exposed in vivo suggest that the PRM 
mifepristone alters the structural organization and ECM composition of the mammary 
gland.  
 
• Epigenetic alterations in breast tissue following PRM treatment, may suggest a 
potential favorable effect in healthy, but also BRCA mutation carriers and other 
women with increased risk for breast cancer. Validation of the surrogate markers used 
















8 FUTURE PERSPECTIVES 
Undesired bleeding irregularities in progestin-only contraceptive users remain an unsolved 
issue despite the attempts that have been adopted to find a treatment. Surely, new approaches, 
or agents already investigated in various trials, may exhibit more favorable results if utilized 
in different treatment regimens. Several candidate components or processes have emerged as 
contributing factors to these bleeding disturbances. With advancing technological 
development, new possibilities for investigations arise. It is important to distinguish between 
bleeding irregularities in new progestin-only users and those that develop after some period 
of use. The underlying mechanisms are probably different and should therefore be addressed 
separately.  
As previously discussed, our knowledge regarding normal breast development and 
differentiation is scarce, in particular during fetal and pubertal life due to, for obvious 
reasons, access limitations to healthy tissue. The mouse has become a widely-used model to 
study molecular and cellular interactions within the tissue, in an attempt to understand the 
biological mechanisms responsible for various events in breast development and ultimately 
cancer initiation. However, even though studies in mice have addressed various issues, 
analogies should be made with caution, in particular considering the complexity of endocrine 
and paracrine signaling. High-throughput technologies can contribute enormously to the 
amount of information. A newer technological advantage, single-cell sequencing, can provide 
the opportunity of studying single cells, which could be more informative than bulk tissue 
where information can be diluted. Interpretation of the data these technologies generate have 
great opportunities for improvement and further standardization. The recent possibility to 
conduct profiling studies on formalin fixed archival tissue will definitely open up for analysis 
of the healthy human breast tissue shedding light into our large knowledge gaps of breast 
tissue homeostasis, regulation and consequently cancer formation.  
Although more investigations are necessary to explore the potential beneficial effects of 
PRMs in the human breast, PR antagonism sheds light into progesterone action. The 
mammary gland of BRCA mutation carriers may serve as a model where regulation or 
dysregulation will help us gain information on healthy breast but also hopefully guide as 
towards risk-reduction strategies for women with BRCA or other mutations in women with 
high risk for breast cancer. In addition, the ability of PRMs to block ovulation and ultimately 
follicular development could hypothetically reduce ovarian cancer risk either by these 
mechanisms per se or by direct impression.  
Continuous treatment with PRMs holds the potential to be used in clinical applications 
covering a broad field within the female reproductive system and PRMs with more specific 
steroid receptor specificity are under development. If an antiproliferative effect of 
mifepristone and other PRMs in the breast could be proven, it would be tremendously 
beneficial in view of expanding indications of PRMs such as for contraceptive purposes and 
more. Prospective clinical trials are necessary to prove this potential. 
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9 POPULÄRVETENSKAPLIG SAMMANFATTNING 
 
Bakgrund till studierna 
En hormonspiral frisätter levonorgestrel (LNG), ett syntetiskt gulkroppshormon (gestagen). 
Det finns numera hormonspiraler med tre olika LNG koncentrationer. I vår studie använde vi 
en spiral (IntraUterine Device – IUD) som innehåller 52 mg LNG (LNG-IUS 52 mg). LNG-
IUS 52 mg ger ett effektivt skydd mot befruktning genom att livmoderhalsens sekret 
förtjockas och spermietransport samt funktion försämras. Dessutom har den en uttalad effekt 
på livmoderslemhinnan som hämmas och minskar menstruationsblödningarna trots att 
ägglossningarna är opåverkade. Hormonspiral är ett mycket säkert preventivmedel som 
används av en hög andel kvinnor i hela världen. Förutom fertilitetskontroll är rikliga 
blödningar en viktig indikation för användning av LNG-IUS 52 mg. Studier har visat att 
blödningsmängden kan minska med upp till 97% under första behandlingsåret och upp till 
50% blir helt blödningsfria under behandlingstiden. En känd orsak till att kvinnor inte finner 
behandling med hormonspiral tillfredsställande är att de första månaderna under 
behandlingen karakteriseras av ett oregelbundet blödningsmönster och småblödningar 
(spotting) vilket drabbar ca 25–62% av användarna. Olika preparat har testats för att minska 
de besvären men än idag finns ingen etablerad behandling. I tidigare studier har man 
observerat att kvinnor som efter behandling med sin första hormonspiral får sin andra insatt, 
har mindre besvär med oregelbundna blödningar och att andelen kvinnor som blir helt 
blödningsfria ökar. Vår teori är att detta beror på att den första hormonspiralen orsakat en 
tunn och hämmad livmoderslemhinna. Om man därför, innan insättning av en hormonspiral, 
kunde ge en förbehandling som orsakar en hämmad slemhinna och blödningsfrihet, skulle det 
initiala blödningsmönstret efter spiralinsättningen förbättras. 
Som förbehandling innan spiralinsättningen har vi använt läkemedlet mifepriston. 
Mifepriston är en så kallad progesteronreceptor-modulator (PRM). Det är ett syntetiskt 
framställt hormon som verkar främst som ett antiprogesteron, d v s hämmar gestagenets 
effekter på receptornivå. Mifepriston utövar ett flertal effekter på det reproduktiva systemet 
beroende på när under menscykeln och i vilken dos det administreras. Studier visar att 
kontinuerlig behandling med mifepriston bland annat kan minska blödningar samt inaktivera 
livmoderslemhinnan och därmed leda till blödningsfrihet efter några dagars behandling. 
Studier har också visat att mifepriston kan krympa muskelknutor i livmodern och minska 
endometriosförändringar och besvär som följd av det. Mifepriston kan även potentiellt 
fungera som ett östrogenfritt preventivmedel.  
Långtidsbehandling med olika PRM har visats orsaka en förtjockad livmoderslemhinna vid 
underökning med ultraljud. Vid undersökning i mikroskop har man sett att de förändringarna 
verkar ha ett typiskt utseende och de uppkommer efter PRM behandling. Förändringarna 
kallas ”progesterone receptor modulator associated endometrial changes” (PAEC). Det 
innefattar bland annat vätskefyllda körtlar och inaktivitet i cellerna trots att 
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livmoderslemhinnan vid undersökning med ultraljud ser förtjockat ut. PAEC anses vara ett 
godartat tillstånd men p g a att mekanismerna bakom dess uppkomst idag är okända vill man 
undersöka dem vidare samt hitta sätt att motverka förändringarna tills vi vet med säkerhet att 
de inte har en negativ inverkan.  
Vidare har gulkroppshormonets och gestagenernas effekt på bröstvävnad genom åren varit 
omdiskuterad med studier som har visat på en möjlig negativ effekt på vävnaden. I en mindre 
klinisk studie i vår grupp kunde vi se en tillväxthämmande inverkan av mifepriston på 
bröstvävnad vilket kan tyda på en skyddande effekt. Vi planerade därför även att undersöka 
mifepristonets effekt på bröstvävnaden hos friska kvinnor och kvinnor med känd ökad risk 
för bröstcancer. 
Studie 1 
I studie 1 undersökte vi hur mifepriston som förbehandling påverkar blödningsmönstret efter 
insättning av LNG-IUS 52 mg. Vi rekryterade 58 friska kvinnor som önskade hormonspiral 
som preventivmedel. Av dessa, lottades 29 till två månaders förbehandling med mifepriston 
och 29 till en kontrollbehandlings- (placebo-) grupp innan spiralinsättningen. Kvinnorna fick 
skatta sina blödningar enligt en förbestämd skala (0: ingen blödning, 1: spotting, 2: sparsam 
blödning, 3: normal blödning och 4: riklig blödning) i en blödningskalender, under 
förbehandlingen med mifepriston/placebo till och med sex månader efter spiralinsättningen. 
Kvinnorna följdes upp regelbundet med ultraljud och blodprover. De fick också fortlöpande 
dokumentera och rapportera in biverkningar. Efter studien kunde vi se att de flesta kvinnorna 
under förbehandling med mifepriston blev blödningsfria. De tycktes också ha lite färre 
blödningsdagar första månaden efter spiralinsättningen än gruppen som erhöll placebo, men 
skillnaden blev inte statistiskt säkerställd. Resterande studietiden var blödningsmönstren 
mellan de två studiegrupperna jämförbar. Inga allvarliga biverkningar rapporterades och 
majoriteten av kvinnorna var nöjda med valet av preventivmedel. Vi kunde således med vår 
behandlingsregim inte påvisa några statistiskt säkerställda skillnader mellan de två 
studiegrupperna. 
Studie 2 
Studie 2 innefattar samma studiedeltagare som Studie 1. Målet med den studien var att 
undersöka livmoderslemhinnan ur en säkerhetsaspekt efter två månaders behandling med 
mifepriston och därefter direkt insättning av hormonspiralen utan att tillåta en 
menstruationsblödning emellan. Ett vävnadsprov från livmoderslemhinnan togs vid 
studiestart, innan kvinnorna började med mifepriston eller kontrollbehandling. Ett nytt prov 
togs 3 månader efter insättningen av hormonspiralen med spiralen på plats. Vävnadsproverna 
bedömdes av en patolog som är expert på PAEC. I den slutliga analysen ingick prover från 9 
kvinnor i mifepriston- respektive 8 från kontrollgruppen. Alla prover var godartade och 
PAEC kunde inte påvisas i någon utav grupperna. Denna behandlingsregim kan således vara 
ett säkert alternativ för livmoderslemhinnan. Med tanke dock på att antalet deltagare som 




Studie tre innefattar samma studiedeltagare som Studie 1. Tidigare har en studie visat att 3 
månaders behandling med mifepriston minskar andelen bröstceller som aktivt delar på sig. 
Ökad celldelning i vävnaden kan ge upphov till genetiska fel och betraktas därför som en 
riskmarkör för uppkomst av cancer. Målet med studien var att utföra analyser med nyare 
metoder och undersöka mifepristonets effekt i bröstvävnaden. Vävnadsproven från bröstet 
togs med en provtagningsnål i lokalbedövning med hjälp av ultraljud. Ett prov togs före 
behandlingsstart och det andra efter 2 månaders behandling med mifepriston eller placebo. I 
slutanalysen ingick 16 kvinnor från mifepriston gruppen. Vi analyserade mRNA (molekyler 
som fungerar som mellanhänder för kodningen av gener till proteiner). När vi jämförde 
proverna innan och efter behandlingen kunde vi se att det mRNA som var överrepresenterat i 
vårt material efter mifepristonbehandling tillhörde extracellulär matrix (ECM). ECM är den 
substans som finns mellan celler. Reglering av ECM, där flera komplexa och ofta okända 
mekanismer och processer är iblandade, spelar en central roll i vävnadens homeostas (balans 
och stabilitet). Obalans i ECM-reglering har visats vara av stor betydelse för cancerinitiering, 
tillväxt och spridning. Framtida studier designade för att undersöka vidare den eventuellt 
skyddande effekten av PRM på bröstvävnad borde ta hänsyn även till ECM och dess 
påverkan.  
Studie 4 
Studie 4 är en hypotesgenererande studie med internationella samarbeten. Huvudfokus var att 
undersöka PRMs epigenetiska effekter i bröstvävnaden hos friska kvinnor men även kvinnor 
med känd ökad risk för att utveckla bröstcancer. Epigenetik undersöker förändringar i 
genuttryck (om en viss gen är aktiv eller inte), oberoende utav förändringar i själva generna. 
Specifika epigenetiska förändringar har visats vara associerade med utveckling av olika typer 
av bröstcancer. Flera experimentella metoder användes för att undersöka effekten av 
mifepriston. Effekterna av mifepriston jämfördes också med effekten av ulipristal acetat, en 
annan PRM. Resultaten talar för att PRM kan ha en skyddande effekt i bröstvävnaden genom 
både epigenetiska och genetiska effekter. De använda metoderna bör dock valideras 
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